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Abstract 
Introduction 
Muscarinic receptors have been identified both in the suburothelium and 
urothelium of the human bladder. It has been proposed that increased release 
of Acetylcholine (ACh) from the urothelial and suburothelial nerves may act on 
suburothelial and detrusor muscarinic receptors, resulting in detrusor 
overactivity (DO). Neuropeptide Y (NPY) is a cholinergic co-transmitter. 
Botulinum neurotoxin type A (BoNT/A) is known to act by blocking the release of 
ACh. We compared expression of M1, M2, M3 receptors, NPY and SNAP-25 in 
patients with DO, controls and following successful treatment with BoNT/A. 
Methods 
Flexible cystoscopy bladder biopsies were obtained from 36 patients with DO at 
baseline, four and sixteen weeks after successful BoNT/A treatment, together 
with 9 asymptomatic controls. Specimens were immunostained using specific 
antibodies to the above mentioned antigens. Immunoreactivity (IR) were 
quantified with image analysis. 
Results 
Reduced levels of M1 IR were noted in DO patients compared to controls. 
Following BoNT/A, there were increases and „normalisation‟ of M1 IR with 
similar changes in the urothelium. Significant similar post-BoNT/A increases 
were seen in M2 IR. Decreased M3 IR was observed at baseline DO compared 
to controls, with significant increases only in the urothelium following BoNT/A. 
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SNAP-25 IR showed no changes. NPY IR increased in DO, with a decreasing 
trend following BoNT/A. Inverse IR correlations were found with frequency and 
urgency.  
Conclusions 
Reduced levels of suburothelial muscarinic receptors in DO are in accordance 
with previous RT-PCR findings, showing reduced mRNA levels in overactive 
bladders. NPY IR is increased and may illustrate upregulated cholinergic 
transmission with DO, similar to ATP. SNAP-25 IR demonstrates the presence 
of BoNT/A sensitive neurones within the suburothelium. Post-BoNT/A changes 
in suburothelial muscarinic receptors and NPY appear compensatory to the 
reduced release of ACh, supporting a neuroplastic effect of BoNT/A on bladder 
afferent pathways as part of its mechanism of action. 
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 I - Introduction  
Chapter 1 - Neural control of the bladder in health and 
disease 
Structure of the lower urinary tract 
 
The role of the lower urinary tract (LUT) is to store and voluntarily periodically 
release urine. For what seems to be a simple function, it is a structure with 
remarkably complicated control exerted by the brain, through the spinal cord 
and peripheral ganglia. The dependence on central nervous control 
distinguishes it from other visceral organ systems such as the gastrointestinal 
tract and cardiovascular system, that can maintain a level of function even after 
extrinsic neural input has been eliminated.  
 
The functional units of the LUT are the bladder and its outlet, which consists of 
the bladder neck, urethra and striated muscles of the urethral sphincter. The 
bladder-urethral complex has two exclusive modes; storage and elimination of 
urine produced from the kidneys. During storage, the bladder fills with urine by 
remaining compliant and staying at low pressure. For the duration of elimination 
the outlet resistance is reduced by relaxation at the external urethral sphincter, 
while the bladder increases its luminal pressure by contracting the surrounding 
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detrusor in a coordinated manner, to expel the urine down the lowered 
resistance urethral channel.  
 
Micturition requires the integration of autonomic and somatic efferent 
mechanisms to co-ordinate the activity of the bladder with that of the urethral 
striated sphincter. Due to this complexity, the LUT is sensitive to injury or 
disease affecting the nervous system.  
 
Structure and function of the bladder 
Structure 
The bladder is a hollow, muscular distensible organ which in the healthy human 
can hold between 400 – 650 ml of urine. The wall consists of three layers (from 
inside to outside): urothelium and a suburothelial layer, detrusor muscle and the 
fibrous adventitia. 
 
The outer most serosa and adventitia is comprised of nerves, blood vessels and 
soft elastic connective tissue for supporting the bladder wall. The detrusor 
muscle layer consists of an inner and outer longitudinal layer of smooth muscle 
with a middle circular layer. The trigone of the bladder is a smooth triangular 
region between the ureteric orifices and the internal urethral orifice derived from 
the caudal end of the mesonephric ducts. The trigone has extensive 
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suburothelial nerve plexuses, considerably more than other parts of the bladder 
(Gosling and Dixon, 1974). 
 
Urothelium 
The urothelium is the epithelial lining of the urinary tract and is composed of 
basal, intermediate and apical layers of large hexagonal cells (diameter of 25-
250μm) known as umbrella cells (Lewis, 2000) (Figure 1). These cells are 
interconnected by tight junctions and are covered on the apical surface by 
crystalline proteins called uroplakins. The barrier function of the urothelium is 
dependent on these tight junctions, uroplakins and lipids, which prevent the 
movement of ions and solutes as well as reduce the permeability of cells to 
small molecules such as water, urea and proteins (Acharya et al., 2004). A 
polysaccharide glycosaminoglycan layer covers the apical layer and is thought 
to prevent bacterial adherence and defend against infection. 
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Figure 1: Superficial layer of human urinary bladder stained with haematoxylin and eosin 
(H+E).  (1) Diameter of superficial umbrella cells depends on degree of bladder stretch. (2) 
Intermediate cells are ~20 µm in diameter (3) Basal urothelial cells are germinal in nature 
and are ~5-10 µm in diameter. (4) Suburothelium. (Reproduced with permission from Prof 
A Gunin, Pathologist). 
 
 
Suburothelium 
The suburothelium comprises of loose fibroelastic connective tissue containing 
axons with their varicosities, fibroblasts, blood capillaries and smooth muscle 
 
21 
cells. The smooth muscle cells have been reported to form a distinct layer 
termed, by analogy with the structure in the intestine, the 'muscularis mucosae' 
although it was noted to be discontinuous and less well defined than in the gut. 
This description has been adopted by urological texts (Wiseman et al., 2003).   
 
Figure 2: Full H+E cross-section of bladder wall showing the constituent layers 
(Reproduced with permission from Prof A Gunin, Pathologist). (1) Urothelium, (2) 
Suburothelium, (3) Muscle Layer. 
 
Immunohistochemistry using pan neuronal markers (PGP 9.5, S-100) has 
shown the presence of a significant number of neurons in this layer, with the 
density of these fibres changing with disease (Dasgupta et al., 1997; Brady et 
al., 2004b). Further structural studies have shown these to be afferent neurones 
presumptively conveying sensory stimuli from the bladder lumen (Dixon and 
Gilpin, 1987; Gabella and Davis, 1998).  
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This layer also contains cells with microscopic characteristics of myofibroblasts 
(Sui et al., 2002; Wiseman et al., 2003). These cells lie in rows below the 
urothelial layer, with their cell bodies parallel to this layer and have close 
apposition to unmyelinated nerves, suggesting functional connectivity (Wiseman 
et al., 2003). It is hypothesised that these cells form part of the sensory 
response mechanism to bladder filling.  
 
Innervation of the bladder 
Efferent innervation of the bladder 
Precise coordination and voluntary control of the LUT is achieved by three sets 
of peripheral nerves: sacral parasympathetic nerves (pelvic nerves), 
thoracolumbar sympathetic nerves (hypogastric nerves and sympathetic chain) 
and sacral somatic nerves (pudendal nerves) (Figure 3).  
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Figure 3: a | Efferent pathways of the female lower urinary tract (reproduced from The 
neural control of micturition; Fowler, Griffiths & de Groat; Nature Reviews Neuroscience 
9, 453-466 (June 2008). Sympathetic fibres (shown in blue); parasympathetic 
preganglionic fibres (shown in green); somatic motor nerves (shown in yellow); b | 
Efferent pathways and neurotransmitter mechanisms that regulate the lower urinary tract. 
 
Parasympathetic outflow 
The sacral parasympathetic outflow provides the major excitatory input to the 
urinary bladder. Preganglionic nicotinic cholinergic fibres originate from the 
intermediolateral region of the sacral spinal cord at the S2-4 spinal segments, 
then travel in the pelvic nerve to ganglia in the pelvic plexus and the bladder 
wall where they synapse (Morgan et al., 1993) (Figure 3). Short post-ganglionic 
fibres excite detrusor bladder smooth muscle via the release of cholinergic 
(acetylcholine) and purinergic (ATP) neurotransmitters acting on P2X receptors 
(Andersson and Arner, 2004) (Ralevic and Burnstock, 1998). Muscarinic 
 
24 
receptors are extensively involved in the control of the bladder as will be 
discussed later. Postganglionic fibres also contain Vasoactive Intestinal 
Polypeptide (VIP) and Neuropeptide Y (NPY); these are thought to be co-
transmitters released with acetylcholine and ATP to modulate the efferent signal 
(Keast and De Groat, 1992).  
 
Cholinergic Transmission 
The release of acetylcholine is the major excitatory mechanism of the human 
bladder. Contraction is mediated by acetylcholine acting on muscarinic 
receptors present on detrusor myocytes and nerve terminals (Chess-Williams, 
2002; Andersson and Arner, 2004; Birder, 2005). There are five different 
muscarinic receptors each encoded by distinct genes (Caulfield and Birdsall, 
1998). The receptors have seven transmembrane regions and are G-protein 
coupled, although the subtypes and second messenger pathways differ. 
M1/M3/M5 are coupled to G proteins Gq/11 and activate phospholipase C to 
upregulate inositol triphosphate production, whereas M2 and M4 are coupled to 
G protein Gi/o and inhibit the activity of adenyl cyclase (Andersson and 
Yoshida, 2003).  
 
mRNA for all muscarinic receptors has been detected in the human bladder; the 
M2 and M3  receptor subtypes being the most frequent in human detrusor 
muscle (Sigala et al., 2002), whereas all five receptors are present in the 
urothelium (Kullmann et al., 2008b). M1, M2
 and M3 subtypes have been 
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detected using immunohistochemistry in urothelium, interstitial cells, nerve 
fibres and detrusor smooth muscle (Mukerji et al., 2006; Bschleipfer et al., 2007; 
Zarghooni et al., 2007).  
 
Muscarinic transmission in detrusor smooth muscle 
M3 receptors are thought to be the most important for mediating detrusor 
contraction. Evidence for this comes from studies using M3 knockout mice. 
Bladder strips from these mice had only 5% of the maximal contractile response 
compared to wild type mice (Matsui et al., 2000). These mice presumably relied 
on their remaining purinergic pathway for efficient voiding (Igawa et al., 2004). 
Even in obstructed rat bladder, the M3 subtype played the predominant role in 
mediating detrusor contraction (Krichevsky et al., 1999). 
 
M3
 receptor activation is thought to cause detrusor contraction through 
phosphoinositide hydrolysis by activating protein kinase C (Andersson et al., 
1991; Jezior et al., 2001). Studies have shown that contraction is dependent on 
Ca2+ ion entry via nifedipine sensitive channels as well as activation of Rho 
kinase, which is thought to increase the sensitivity of the contractile machinery 
to Ca2+ ions (Schneider et al., 2004) (Figure 4).  
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Figure 4: Muscarinic receptor mediated contraction. Stimulation of M3 receptors by Ach 
causes contraction of detrusor muscle via activation of protein kinase C and rho-kinase, 
resulting in an influx of Ca
2+
 ions. An indirect action of ACh is to inhibit the production of 
cAMP and reverse the relaxation caused by NA on the β-adrenoceptor, promoting 
contraction. Reproduced from Abrams & Andersson. Muscarinic receptor antagonists for 
overactive bladder. BJU International 100 (5), 987-1006: 2007 
 
M2 receptor activation can contract the bladder indirectly by inhibition of 
adenylate cyclase and reversing sympathetically (i.e. beta-adrenoceptor) 
mediated relaxation, (Hegde et al., 1997). Knockout mice studies have shown 
that M2 receptors may indirectly mediate bladder contractions by enhancing the 
contractile response to M3 receptor activation and that minor M2 receptor 
mediated contractions might occur (Ehlert et al., 2005).  
 
In the healthy bladder, M2 receptors seem to have a lesser contribution to 
contraction compared to M3 receptors but this may change with disease states. 
In the denervated rat bladders, M2 receptors or a combination of M2 and M3 
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receptors contribute to the contractile response (Braverman et al., 1998). In 
obstructed hypertrophied rat bladders there was an increase in total muscarinic 
receptors and M2 receptor density, with a decrease in M3 receptor density 
(Braverman and Ruggieri, 2003). This has not been seen in human detrusor 
studies. Pontari et al. examined whether there was shift from M3 to M2 receptor 
mediated contraction in patients with NDO following traumatic cervical injuries. 
Bladder strips from those patients were compared to bladders from organ 
donors and showed that contractions in NDO patients could partly be mediated 
by M2 receptors (Pontari et al., 2004). This was further studied by Stevens et al. 
in subjects with NDO or IDO undergoing clam cystoplasty compared to patients 
undergoing cystectomy for bladder cancer using subtype selective antagonists. 
They showed that although the contraction was enhanced in DO, there was no 
change in the receptor subtype (M3) contributing to the contraction in the 
disease state (Stevens et al., 2007).  
 
Presynaptic nerve terminals  
To activate post-junctional muscarinic receptors, ACh controls its own release 
by muscarinic auto-receptors which are located prejunctionally on cholinergic 
nerve terminals within the bladder. The inhibitory pathway allows for a 
muscarinic feedback mechanism to reduce the release of ACh from the 
cholinergic terminals. The inhibitory prejunctional receptors have been classified 
in rabbit as M2 and in humans as M4 (Inadome et al., 1998; D'Agostino et al., 
2000; Takeuchi et al., 2008), whereas the M1 subtype seems to facilitate 
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cholinergic transmission in rat and rabbit bladders (Somogyi and de Groat, 
1992; Inadome et al., 1998). This same facilitatory mechanism has been shown 
in human bladder and is mediated by influx of extracellular Ca2+ into the 
parasympathetic nerve terminals via L- and N-type Ca2+ channels (Somogyi and 
de Groat, 1999). Prejunctional M1-muscarinic receptors have been identified on 
cholinergic nerve terminals innervating the bladders of several species, where 
they enhance transmitter release (Somogyi and de Groat, 1992; Somogyi et al., 
1994) and potentiate bladder contractions to electrical field stimulation, 
(Somogyi and de Groat, 1999) promoting efficient voiding.  
 
In chronic spinal cord transected rats, this facilitation exhibits plasticity and has 
been found to be up-regulated and primarily mediated by M3 receptors 
(Somogyi et al., 2003). Conversely, inhibitory M2 and M4 prejunctional receptors 
may function to promote urinary storage in pathological states such as bladder 
denervation or spinal cord injury (Chapple, 2000). 
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Functional role of muscarinic receptors 
Pharmacological studies 
Molecular studies have classified muscarinic receptors into five subtypes (M1 – 
M5) (Caulfield and Birdsall, 1998). Radioligand studies have shown the bladder 
of most species including man are principally M2 and M3 receptors, with the 
former predominating (Hegde and Eglen, 1999). These early studies were not 
sensitive enough to detect receptors in the urothelium and suburothelium, and 
the potential importance of this superficial layer was not recognised.  
 
Until recently, the functional role of muscarinic receptors has been interpreted 
from agonist and antagonist studies which had preferential activity for a 
particular subtype e.g. pirenzepine, darifenacin and 4-DAMP. These studies 
suggested that M3 receptors primarily mediate the direct contractile response to 
agonists in the bladder (Hegde et al., 1997; Chess-Williams, 2002). The initial 
evidence was that M3 receptors mediated contraction via activation of 
phospholipase C, however further studies have shown that contraction is 
dependent on entry of extracellular calcium through L-type calcium channels 
and activation of Rho kinase (Schneider et al., 2004). Pharmacological studies 
have not demonstrated any role of M2 receptors in mediating contractile 
responses, and although their role in disease states (NDO) may become more 
important (Pontari et al., 2004), this has been challenged (Stevens et al., 2007).  
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Urothelium derived inhibitory factor 
The urothelium was traditionally viewed as a passive membrane barrier 
between the urinary tract and urine itself. There is increasing evidence that the 
suburothelium and urothelium express a range of receptors that participate in 
sensory function by releasing neurotransmitters in response to distention and 
receptor activation (Fry et al., 2004; Abrams et al., 2006; Apostolidis et al., 
2006; de Groat, 2006).  
 
There are a number of factors released by the urothelium which decrease 
detrusor muscle tone. A diffusible "urothelial derived inhibitory factor" (UDIF) 
released by muscarinic or histamine receptor stimulation, has been shown to 
inhibit detrusor contraction in a pig by about 35% (Hawthorn et al., 2000; 
Templeman et al., 2002; Murakami et al., 2007).  Muscarinic agonists stimulate 
the release of this inhibitory factor from the human urothelium; the factor is 
distinct from nitric oxide and it persists in the presence of beta-adrenoceptor 
blockade or cyclooxygenase inhibition (Chaiyaprasithi et al., 2003). The release 
of UDF is also reduced during drug induced inflammation (Inci et al., 2003). 
 
Isoprenaline, a β-adrenoreceptor agonist, causes detrusor muscle relaxation but 
does not appear to act via NO. Isoprenaline may act directly by relaxing the 
detrusor muscle or by stimulating the release of this UDIF, as it is more potent 
at inhibiting carbachol contractions in the presence of the urothelium (Murakami 
et al., 2007).  Further experiments have shown that urothelial beta-
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adrenoceptors induce the release of a UDIF, which inhibits the beta-
adrenoceptor agonist-induced relaxation of human detrusor smooth muscle and 
that  this inhibitory mechanism does not involve NO (Otsuka et al., 2008). 
 
Gene Knock Out studies 
M3 receptor knockout (KO) mice had their responses to carbachol (muscarinic 
agonist) attenuated by 95% (Matsui et al., 2000). Although the M3 KO mice had 
larger voiding intervals and bladder capacity, they voided to completion and 
showed no functional impairment, suggesting possible compensation by 
alternative muscarinic receptors or other non-cholinergic neurotransmitter 
systems (Hegde, 2006). M2 and M3 KO mice showed complete loss of 
contractile responses, implying that M2 receptors mediated a small direct 
contractile response and provided the compensatory response seen in the M3 
KO mice (Matsui et al., 2002). Only male mice showed urinary bladder 
distension, but all animals were still viable.  
 
Whereas pharmacological studies were limited in their ability to discern whether 
the prejunctional inhibitory auto-receptors were M2 or M4 subtypes, this was 
clarified by M4 KO animals, showing M4 receptor subtypes provided an inhibitory 
negative feedback mechanism on ACh release (Zhou et al., 2002). The 
facilitatory role of M1 receptors is yet to be confirmed with KO studies.  
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Sympathetic pathways 
These originate from the T11 – L2 segments of the cord and run in inferior 
mesenteric ganglia or pass through the paravertebral chain to enter the bladder 
via the hypogastric and pelvic nerves respectively. Their main function is 
thought to be the relaxation of the detrusor muscle via β3 adrenoceptors and 
excitation of the urethral sphincter complex via release of norepinephrine on α1 
adrenoceptors (Andersson and Arner, 2004). Sympathetic inputs also modulate 
cholinergic nicotinic neurotransmission in the pelvic ganglia.  
 
Somatic efferent pathways 
Cells in the circumscribed region of lateral ventral horn in the S2-S4 segment of 
the sacral cord (Onuf‟s nucleus) (Onufrowicz, 1899) give rise to the motor 
innervation of the urethral striated sphincter. Motor nerves pass in the pudendal 
nerve and innervate the neuromuscular junctions of the sphincter muscle.  
 
Coordination of activity by the CNS 
The process of voiding is initiated by the sensation of bladder fullness and 
indeed the overall motivation of the behaviour is to attain relief from this 
increasingly intense sensation of bladder filling, 
 
The prefrontal cortex is postulated to be involved in the decision of whether or 
not to micturate (Fowler, 2006). Once the decision to void is made by the 
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prefrontal cortex, there is activation of the insula, hypothalamus and para-
aqueductal gray (PAG), resulting in activation of the pontine micturition centre 
(PMC) (Blok et al., 1997; Blok et al., 1998; Fowler et al., 2008). There is spinal 
transmission of activity to sacral segments of the cord, with initial inhibition of 
external urethral sphincter motor activity, followed by activation of bladder 
parasympathetic efferents. A combination of excitatory and inhibitory 
neurotransmitter release results in coordinated voiding (Figure 5). Afferent 
activity feedback to the PAG and PMC during a sustained void allows complete 
voiding to occur with subsequent cessation of activity. 
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Figure 5: Neural circuits that control continence and micturition. a | Urine storage 
reflexes. During the storage of urine, distention of the bladder produces low-level vesical 
afferent firing. This in turn stimulates the sympathetic outflow in the hypogastric nerve to 
the bladder outlet (the bladder base and the urethra) and the pudendal outflow to the 
external urethral sphincter. These responses occur by spinal reflex pathways and 
represent guarding reflexes, which promote continence. Sympathetic firing also inhibits 
contraction of the detrusor muscle and modulates neurotransmission in bladder ganglia. 
A region in the rostral pons (the pontine storage centre) might increase striated urethral 
sphincter activity. b | Voiding reflexes. During the elimination of urine, intense bladder-
afferent firing in the pelvic nerve activates spinobulbospinal reflex pathways (shown in 
blue) that pass through the pontine micturition centre. This stimulates the 
parasympathetic outflow to the bladder and to the urethral smooth muscle (shown in 
green) and inhibits the sympathetic and pudendal outflow to the urethral outlet (shown in 
red). Ascending afferent input from the spinal cord might pass through relay neurons in 
the peri-aqueductal grey (PAG) before reaching the pontine micturition centre. Note that 
these diagrams do not address the generation of conscious bladder sensations, nor the 
mechanisms that underlie the switch from storage to voiding, both of which presumably 
involve cerebral circuits above the PAG. R represents receptors on afferent nerve 
terminals. Reproduced from (Fowler et al., 2008). 
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Normal Bladder Function 
One of the aspects of human behavioural development is the ability to plan to 
void at a socially acceptable time and place. This involves being aware of one‟s 
environment and the availability and accessibility of a toilet, together with 
attentiveness to sensory signals indicating bladder fullness. It is critical that the 
brain can be given sufficient time and warning prior to the requirement to void. 
The vast majority (99%) of our normal lives we are in storage mode (Fowler, 
2006).  
 
Urodynamic studies in healthy controls performed 5 years apart have shown 
that the first sensation of bladder fullness occurs approximately at 40% of 
capacity (Wyndaele and De Wachter, 2002). The first desire to void (FDV) has 
been defined by the International Continence Society (ICS) as “the feeling, 
during cystometry, that would lead the patient to pass urine at the next 
convenient moment, but voiding can be delayed if necessary”, and occurs at 
60% of capacity (Abrams et al., 2002; Wyndaele and De Wachter, 2002). At 
90% capacity, patients report a strong desire to void which the ICS define as “a 
persistent desire to void without the fear of leakage”. Psychological mental state 
can alter the perception of bladder fullness similar to pain (Valet et al., 2004); 
anxiety can increase the level of desire to void whereas distractions reduce it.  
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Afferent pathways  
Sensations of bladder fullness are conveyed to the spinal cord in the pelvic and 
hypogastric nerves (Janig and Morrison, 1986). Input from the bladder neck and 
urethra are conveyed in the pudendal and hypogastric nerves (Morisson et al., 
2005). The most important components of the sensory inputs are the small 
myelinated (Aδ) and unmyelinated (C) fibres which convey impulses from 
tension and volume receptors as well as nociceptors in the bladder to neurones 
in the spinal cord (de Groat, 1997). The afferent nerves are located in the 
smooth muscle, as well as the serosal and suburothelial layers of the bladder 
(Gosling and Dixon, 1974). 
 
Aδ fibres 
Aδ fibres are mechano-sensitive, respond to passive distention and active 
contraction and convey information regarding bladder filling (Janig and 
Morrison, 1986). Afferent pathways from the bladder project into Lissauer‟s tract 
and then synapse onto interneurones. These neurones send long projections 
transmitting sensory input into supraspinal centres like the PAG and gracile 
nucleus (Blok et al., 1995). The PAG relays information during filling to the 
PMC, maintaining an excitatory effect on Onuf‟s nucleus. This in turn maintains 
sphincter contraction and inhibits the Parasympathetic Motor Nucleus (PMN) 
inhibiting bladder contraction. When the bladder is sufficiently full and volitional 
control is relaxed, the PAG signals the PMC to initiate the micturition reflex by 
inhibiting Onuf‟s nucleus and activating the PMN. This integrated system 
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receives higher control from the hypothalamus, cingulate gyrus and forebrain to 
ensure social and emotional control over initiation or inhibition of the micturition 
reflex, by influencing the activity of the PAG or PMC itself (Fowler et al., 2008). 
 
C-fibres 
Based on their sensitivity to capsaicin, it is thought that 70% of the afferent 
nerves from the bladder are C-fibres (Yoshimura and de Groat, 1999). C-fibres 
are thought to be normally quiescent and only become activated during 
inflammation, irritation or cooling (Fall et al., 1990), therefore being insensitive to 
bladder filling under physiological conditions. C-fibre afferents are sensitive to 
noxious stimuli like the vanilloids capsaicin and resiniferatoxin (RTX) as well as 
tachykinins, NO, ATP, temperature and pH (Dasgupta et al., 2000; Rong et al., 
2002; Cheng and de Groat, 2004). These substances modulate afferent activity 
excitability and thus alter sensory transduction. Both Aδ and C-fibres have cell 
bodies located in the dorsal root ganglia at S2-S4 and T11-T12 spinal 
segments. These axons synapse with interneurones which project to higher 
brain centres.  
 
ATP is thought to be a modulator of afferent nerve excitability, as 
immunohistochemical studies have revealed that P2X and P2Y receptors are 
expressed in the bladder afferent nerves and urothelial cells (Lee et al., 2000). 
There is now considerable evidence suggesting that extracellular ATP 
modulates afferent nerve excitability by activating P2X receptors (Burnstock, 
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2000; Yu and de Groat, 2008). The purinergic receptor P2Y6 is thought to be 
present on suburothelial myofibroblasts in the suburothelium. These cell 
respond to ATP by generating an intracellular Ca2+ transient (Sui et al., 2006).  
 
Bladder sensory nerves and innervation of the urothelium 
Both humans and animals have a dense nexus of sensory nerves in the 
suburothelial layer of the urinary bladder (Gosling and Dixon, 1974; Gabella and 
Davis, 1998). Terminal fibres of these nerves project through the suburothelium, 
occasionally reaching the urothelium (Birder et al., 2001; Wiseman et al., 2002). 
The plexus is thickest in the neck of the bladder and in the initial portion of the 
urethra, becoming progressively less dense and sparse towards the dome 
(Gabella and Davis, 1998).  
 
Numerous studies have shown both afferent and autonomic efferent nerves are 
located in close proximity to the urothelium (Birder et al., 2001; Dickson et al., 
2006). Peptide and TRPV-1 immunoreactive fibres are located in a plexus 
underneath the urothelium and these extend into the urothelium (Avelino et al., 
2002). Cholinergic and adrenergic fibres have also been detected here.  
 
The urothelium is no longer regarded as a passive barrier; it has substantial 
sensory and signalling properties (Birder et al., 1998) and engages in reciprocal 
chemical communication with the adjacent nerves in the suburothelium (Birder 
et al., 2001; de Groat, 2006; Birder and de Groat, 2007). Studies over several 
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years indicate that urothelial cells display a number of properties similar to those 
of sensory neurons such as nociceptors and mechanoreceptors, and that both 
types of cells use diverse signal-transduction mechanisms to detect 
physiological stimuli (Birder and de Groat, 2007). 
 
Several substances have been shown to be released from urothelial cells 
following physical and chemical stimulation: ATP, NO, substance P, 
acetylcholine, adenosine, UDIF, cytokines and prostanoids (Birder and de 
Groat, 2007).  
 
These substances contribute to autocrine and paracrine mechanism of signal 
transmission. Autocrine signalling is where a cell releases a neurotransmitter 
that binds to receptors on the same cell type, leading to changes within that cell 
e.g. release of ACh from the urothelium acting on the urothelium itself. This is in 
contrast to paracrine signalling, in which the target is near the signal releasing 
cell e.g. release of ACh from the urothelium acting on underlying nerve fibres 
and cells in the suburothelium. The signalling molecules involved degrade very 
quickly, are taken up quickly or can travel only short distances, therefore limiting 
their effect to the local surrounding environment.  
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Figure 6: Hypothetical model depicting possible interactions between bladder afferent 
and efferent nerves, urothelial cells, smooth muscle and myofibroblast. Urothelial cells 
can be activated by either autocrine or paracrine mechanisms. Stimulations of urothelial 
cells can release mediators that activate bladder nerves. Reproduced from Mechanisms 
of disease: involvement of the urothelium in bladder dysfunction. Nat Clin Pract Urol. 
Jan;4(1):46-54. Review (Birder and de Groat, 2007). 
 
Sensory molecules, receptors and ion channels of the urothelium 
There is expression of a multitude of receptors (nicotinic, noradrenergic α and β, 
muscarinic, tachykinin, purines P2X and P2Y, adrenergic, bradykinin, 
neurotrophin Trk-A and p75, vanilloid) responding to released neurotransmitter 
(Figure 6). The urothelium has a close physical association with afferent nerves 
which can relay sensory information back to the spinal cord. (Beckel et al., 
2006; Birder and de Groat, 2007). Further examples of identified neuronal 
„sensory molecules‟ include mechanosensitive Na+ channels and a number of 
TRP channels (TRPV1, TRPV2, TRPV4 and TRPM8) (Ferguson et al., 1997; 
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Chopra et al., 2005; Beckel et al., 2006).  There is evidence that urothelium 
expresses the full complement of muscarinic receptors (M1-M5) (Chess-
Williams, 2002; Abrams et al., 2006; Bschleipfer et al., 2007). 
 
ATP 
The role of urothelial released ATP as part of the afferent system was first 
identified when it was found to be released with bladder distension and was 
increased in experimental NDO (Ferguson et al., 1997). P2X and P2Y purinergic 
receptor subtypes are expressed in the urothelium, nerves and myofibroblasts, 
suggesting an important role in cell communication. ATP causes an increase in 
intracellular Ca2+ release in those cells (Wu et al., 2004). Intravesical 
administration of ATP increases firing of afferent terminals and enhances the 
firing as a result of bladder distension (de Groat, 2006). Its intravesical 
administration in rats has been found to induce bladder overactivity and this 
effect was blocked by P2X antagonists (Nishiguchi et al., 2005). P2X3 receptors 
have been identified in the urothelium in humans (Elneil et al., 2001), suggesting 
an autocrine role for urothelial released ATP. 
 
Bladder efferent activity from P2X3 knockout mice was reduced compared to 
normal mice during bladder distension, strongly suggesting a sensory role for 
ATP released from the urothelium acting at this receptor (Vlaskovska et al., 
2001). It is thought that 90% of bladder afferents are excited by ATP, activating 
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P2X2/3 receptors (Zhong et al., 2003), and that its main role is in autocrine and 
paracrine signalling from the urothelium.  
 
Capsaicin and TRPV1 
Another important group of urothelial sensory molecules is the transient receptor 
potential cation channel family (TRPV). TRPV1 is thought to have a role in 
nociception as well as normal bladder function. The heat and pain induced by 
chilli peppers is caused by stimulation of TRPV1 receptors (Caterina et al., 
1997). This ion channel receptor protein is activated by moderate heat, protons 
and lipid metabolites such as anandamide. TRPV1 is expressed on urinary 
bladder c-fibres and on urothelial cells (Birder et al., 2001; Lazzeri et al., 2004). 
TRVP1 is thought to amplify the response to various stimuli especially in the 
irritated bladder. However, in TRPV1 knock-out mice it was observed that 
bladder function was altered and there were reductions in ATP release (Birder 
et al., 2002) indicating that TRPV1 participates in normal bladder function and is 
part of the mechanically evoked urothelial purinergic signalling mechanism. 
 
Basal cell layer TRPV1 immunoreactivity has been shown to be significantly 
increased in NDO compared with control bladders. Following successful 
treatment with RTX, basal cell layer and total urothelial TRPV1 immunoreactivity 
decreased significantly (Apostolidis et al., 2005a). Decreases in the basal cell 
layer TRPV1 immunoreactivity after RTX were comparable to the parallel 
decreases in suburothelial TRPV1 nerve fibres (Brady et al., 2004b).  
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Studies have found that symptoms of sensory urgency are associated with 
increased TRPV1 expression in the trigonal mucosa (Liu et al., 2007). 
 
 The TRPV4 cation channel has been found to mediate stretch-evoked Ca2+ 
influx and ATP release in primary urothelial cell cultures, suggesting this is a 
sensor molecule in detecting bladder distension (Mochizuki et al., 2009). Further 
evidence that TRPV4 plays a critical role in urothelium-mediated transduction 
comes from TRPV4-deficient mice, which exhibit a lower frequency of voiding 
contractions as well as a higher frequency of non-voiding contractions (Gevaert 
et al., 2007). Stretch evoked ATP release has been shown to be decreased in 
isolated whole bladders from TRPV4-deficient mice. The role of TRPV4 in 
normal human physiology and pathophysiology is yet to be determined, but if 
found to be critical,  TRPV4 antagonists could potentially modulate the sensory 
transduction process and open up a novel class of drug. 
 
Suburothelium  
Together with the urothelium, the suburothelium plays a substantial role in 
sensory function. Transmission electron microscopy has revealed a complex 
sensory nexus of vesicle packed naked axons. The exact contents of these 
dense core and clear vesicles are yet to be elucidated (Wiseman et al., 2003).  
 
Immunohistochemical techniques have demonstrated unmyelinated nerves 
staining for CGRP, substance P, VIP, acetylcholine and ATP. TRPV1 and P2X3 
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immunoreactive fibres have been identified within the suburothelium and 
detrusor layers (Yiangou et al., 2001).  
 
Suburothelial myofibroblasts 
There is a layer of cells beneath the urothelium in the lamina propria that have 
microscopic characteristics of myofibroblasts (Wiseman et al., 2003). These 
cells have been described “with the cytological characteristics of both fibroblasts 
and smooth muscle cells, that included bundles of fine cytoplasmic filaments, 
dense bodies, linear arrays of subsurface vacuoles, and the presence of an 
interrupted basal lamina” with close apposition to suburothelial unmyelinated 
nerve fibres (Wiseman et al., 2003) . 
 
There are also cells in the detrusor layer with similar appearances termed 
“interstitial cells”, but it is not known whether they are of the same type as the 
suburothelial myofibroblasts. They have been found to be innervated by fibres 
that increase cellular cGMP and may also release NO (Smet et al., 1996). The 
detrusor interstitial cells lack the fibronexus and abundant rough ER of the 
archetypal myofibroblast and thus can be differentiated from myofibroblasts by 
using transmission electron microscopy (Drake et al., 2006). 
 
The suburothelial myofibroblasts characteristically lie in rows with their cell 
bodies and projections parallel to the base of the urothelium. They display cell to 
matrix connections and intracellular stress fibres (Drake et al., 2006) and 
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respond to exogenous ATP by generating intracellular Ca2+ transients (Wu et 
al., 2004). Immunolabeling has been possible with vimentin and connexin 43 
(Cx43) antibodies, showing that they form a syncytium through extensive Cx43 
gap junction coupling (Fry et al., 2007).  
 
Physiologically suburothelial myofibroblasts cells show spontaneous intracellular 
Ca2+ and membrane potential transients. ATP is thought to initiate these 
membrane potentials via the P2Y6 receptor subtype, but these can be 
generated by reduction of extracellular pH and generation of nitric oxide (Fry et 
al., 2007). Signals initiated by one group of cells can be transmitted 
considerable distances in the suburothelial layer. It is hypothesised that the 
close relationship between nerves and myofibroblasts allows for variable 
amplification of an afferent signal in response to ATP release. Suburothelial 
myofibroblasts respond to several physiological and artificial interventions that 
are known to influence bladder activity either directly or through activation of 
sensory mechanisms. It is proposed that these cells could modulate bladder 
responses by being a link between urothelial signalling during bladder filling and 
afferent fibre stimulation (Sui et al., 2008).  
 
In the rat model of NDO, there was marked upregulation of suburothelial gap 
junctions Cx26 and Cx43 (urothelial and suburothelial respectively) in neonatal 
and spinal cord transected animals. Administration of a gap junction blocker was 
shown to reduce spontaneous bladder contractions (Ikeda et al., 2007). 
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Immunofluorescence studies have also shown an increased number of gap 
junction protein Cx43 on myofibroblasts in human NDO and IDO, which is not 
altered by successful BoNT/A treatment (Roosen et al., 2008).  
 
Non-neuronal cholinergic system in the urothelium and suburothelium 
Muscarinic receptors have been detected in the urothelium and suburothelium 
but their functional importance has not been defined as yet (Mansfield et al., 
2005; Mukerji et al., 2006; Mansfield et al., 2007).  
 
It has been suggested that non-neuronal ACh synthesised in cells other than 
parasympathetic neurons may act in an autocrine or paracrine manner (Hanna-
Mitchell et al., 2007). The traditional view of ACh acting solely as a 
neurotransmitter had to be revised based on the findings published both early 
and late in the last century, demonstrating the non-neuronal cholinergic system. 
Cholinergic communication is highly conserved from the beginning of life and is 
found in primitive uni- and multicellular organisms. (Horiuchi et al., 2003). 
Evidence for ACh synthesis is not only provided by positive anti-ChAT 
immunoreactivity, but ChAT enzyme activity and/or ACh content have also been 
determined in the majority of epithelial cells e.g. vagina, urothelium, 
endothelium, cornea and placenta (Wessler and Kirkpatrick, 2008). Knowledge 
of the release mechanism of ACh from the various epithelial cells is scarce. 
Organic Cation Transporters (OCT) are believed to be involved in mediating the 
release of non-neuronal ACh. In numerous organ systems, non-neuronal ACh 
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has been found to modify signal transduction via nicotinic and muscarinic 
receptors (Wessler and Kirkpatrick, 2008).  
 
Immunohistochemical staining of human bladder tissue with antibody against 
choline acetyltransferase has shown the presence of a cholinergic system in the 
urothelium / suburothelium. Tetrodotoxin (TTX) has been used to block neuronal 
release of ACh, with experiments demonstrating that a small amount of ACh 
was released despite the presence of TTX, implying a non-neuronal system. 
Stripping the urothelium off detrusor specimens has shown that the urothelium 
contributed significantly to overall ACh release by the bladder (Yoshida et al., 
2004), and is likely to be the source of the non-neuronal ACh. Release of non-
neuronal (TTX resistant) ACh has been shown to be evoked by stretch and to 
increase with age (Yoshida et al., 2008). 
 
There is evidence to suggest that urothelial ACh is not stored and released via 
vesicles, as Vesicular Acetylcholine Transporter (VAChT) was not found in 
urothelial cells and brefeldin, a chemical that blocks vesicle formation, did not 
block the release of ACh from urothelial cells (Hanna-Mitchell et al., 2007). Non-
neuronal urothelial ACh release occurred in the storage phase of the voiding 
cycle and from this work, proposals were made that anti-muscarinic drugs might 
be acting at the urothelial/suburothelial level (Yoshida et al., 2004). In-vivo 
studies on mice have suggested that muscarinic receptor agonists and 
acetylcholine have an inhibitory role in bladder afferent activity, and that this 
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effect is not mediated by M3 receptors (Daly et al., 2010). It has been suggested 
that the alterations of non-neuronal cholinergic system may contribute to the 
pathophysiology of human bladder. 
 
In a study looking at muscarinic receptors in human bladder, Mukerji et al. 
showed that there was M2 and M3 receptor immunoreactivity in the urothelium, 
nerve fibres and detrusor layers. “Myofibroblast like staining” was stated by 
authors to be observed in the suburothelial and detrusor layers when stained for 
M2, M3 and vimentin. There is currently controversy with regard to pathological 
changes of receptors with detrusor overactivity. Mukerji et al. showed significant 
increase in suburothelial myofibroblast like M2 and M3 staining in patients with 
Idiopathic Detrusor Overactivity (IDO) compared to control subjects, whereas 
Mansfield et al. showed a decrease in urothelial and suburothelial M3 mRNA 
expression in IDO patients compared to controls (Mukerji et al., 2006; Mansfield 
et al., 2007).  Immunocytochemical evidence from guinea pigs has shown the 
presence of M3 receptors located on interstitial cells in the suburothelium 
(Gillespie et al., 2003). It has been proposed that suburothelial muscarinic 
receptors predominantly detect the non-neuronal acetylcholine release from the 
urothelium. 
 
Immunohistochemical studies have demonstrated all five muscarinic receptors 
being present on human urothelium, with M2 and M3 subtypes being the most 
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common (Bschleipfer et al., 2007). M1 IR was found to be highly localised to 
basal cells in the urothelium. 
 
It is clear that the functional role of muscarinic receptors in the urothelium and 
suburothelium is highly complex and not well understood; further work is 
required to clarify their roles in normal and pathological bladder function. It is 
controversial as to whether anti-muscarinic agents in the treatment of DO and 
OAB function at the level of the muscle or on the sensory mechanism involving 
the complex of urothelium, suburothelium and myofibroblasts.  
 
Neuropeptide Y (NPY) 
Peptides such as ATP and NPY have been implicated as co-transmitters in 
cholinergic pathways as well as the sympathetic nervous system. Neuropeptide 
Y is a 36 amino acid peptide and is the most abundant peptide neurotransmitter 
in the normal human bladder, with a rich distribution in the detrusor muscle as 
well as in the suburothelium (Crowe et al., 1991; Dixon et al., 2000). In the 
human body NPY coexists with noradrenaline (NA) in neurones in the brainstem 
(Everitt et al., 1984), peripheral sympathetic ganglia on blood vessels (Ekblad et 
al., 1984) and mouse vas (Stjarne et al., 1986). The presence of NPY in 
parasympathetic cholinergic neurones has been demonstrated in the otic and 
internal carotid ganglia (Suzuki et al., 1990), major pelvic ganglia in the rat 
(Keast, 1991) and ganglia of the guinea pig and human urinary bladder (James 
and Burnstock, 1988; Dixon et al., 2000).  
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95% of all cholinergic neurones of the human detrusor muscle were found to 
also contain neuropeptide Y (Dixon et al., 2000).  In peripheral neurones, NPY 
appears to have several functions, including a direct post-junctional excitatory 
action as well as pre and post junctional modulatory effects. In the vas deferens, 
NPY acts pre-junctionally to inhibit NA release (Lundberg and Stjarne, 1984; 
Ellis and Burnstock, 1990) and post-junctionally to enhance the action of NA 
(Ellis and Burnstock, 1990), but does not directly induce smooth muscle 
contraction.  
 
NPY has a inhibitory regulatory role on the release of cholinergic and adrenergic 
neurotransmitters and induces a reversible reduction of the contractile response 
to field stimulation of the urinary bladder (Lundberg et al., 1984; Tran et al., 
1994). NPY also reduces the cholinergic component of electrically induced 
contraction of rat detrusor strips (Zoubek et al., 1993). The inhibition is due to its 
prejunctional action possibly by Y2 subtype receptors to inhibit ACh release 
(Wahlestedt et al., 1990; Tran et al., 1994).  
 
Changes showing nerve degeneration and regeneration have been described in 
bladder detrusor biopsies from NDO patients (Haferkamp et al., 2003a). Lower 
densities of cholinergic fibres have also been described in NDO patients with 
meningomyelocele, indicating partial denervation of the smooth muscle 
(German et al., 1995).  Drake et al. found that there was a reduction of NPY 
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containing nerves corresponding to partial nerve degeneration in NDO patients 
with heterogenous spinal cord injury (Drake et al., 2000).  Haferkamp et al. 
showed a reduced frequency of NPY containing nerves in the detrusor of NDO 
patients, without a corresponding decrease in PGP 9.5 immunoreactive nerve 
fibres. They proposed that this reduced the inhibitory action of NPY on detrusor 
overactivity contractions (Haferkamp et al., 2006). The role of NPY in the 
suburothelium is unknown and changes in human DO are yet to be elucidated. It 
is postulated that NPY containing nerves in the suburothelium may be 
upregulated in response to enhanced cholinergic pathway in DO.  
  
 
52 
Bladder dysfunction - Overactive Bladder and Detrusor 
Overactivity 
Current causation theories  
The precise cause of OAB and DO has not been elucidated so far. There are 
animal experimental models of DO but not OAB, due to the symptomatic nature 
of the diagnosis. Most animal work is careful scientific observation between 
control animals and those with induced DO, and postulating their importance in 
the mechanisms that underlie DO. Three main theories have been proposed 
regarding the cause of DO. 
 
It is likely that the true cause of DO and OAB may be different in different 
situations or individuals, and may involve one or more of the hypotheses and 
each hypothesis is not mutually exclusive. There are some overlaps between 
the each of these models.  
 
Myogenic Theory 
This theory is based on the findings of altered properties of detrusor myocytes 
which are thought to be responsible for the involuntary detrusor contraction 
(Brading, 1997). Brading's theory is based on partial denervation setting in 
motion changes in detrusor physiological properties leading to supersensitivity 
to agonists, increased spontaneous excitability and increased electrical coupling 
between cells. Due to a lower threshold of excitability, a smaller local stimulus 
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may initiate a myogenic contraction of the entire bladder giving rise to DO. The 
greater excitability of smooth muscle cells are thought to come about due to 
increases in gap junctions and changes in cellular ultrastructure with the 
formation of protrusion junctions and ultra-close abutments, facilitating 
propagation of any electrical activity (Elbadawi et al., 1993; Haferkamp et al., 
2003b). The local electrical stimulus can be initiated by stretch detected by 
afferent fibres or by normal firing in efferent pre-ganglionic fibres. Brading 
postulates that these changes come about as a response to a reduction in the 
normal excitatory input to the bladder, and do not preclude alteration in neural 
pathways of micturition.  
 
Neurogenic Theory  
This theory supported by de Groat suggests that changes in peripheral and 
central neural pathways can lead to detrusor overactivity (de Groat, 1997). It is 
based on 1) a reduction in peripheral or central inhibition, 2) an enhancement of 
excitatory transmission in the micturition reflex pathway, 3) increased afferent 
input and 4) emergence of bladder reflexes that are resistant to central 
inhibition. The above may not be present in all cases and different causes may 
be present in different groups of patients.   
 
Disruption of suprapontine circuits by anterior cerebral lesions or degeneration 
of dopaminergic neurones in Parkinson‟s disease removes inhibitory control on 
the PMC. Studies looking in rat models of cerebral infarction suggest 
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suprapontine lesions alter signalling to the PMC, giving rise to DO (Fowler, 
1999; Yokoyama et al., 2002; Yokoyama et al., 2003). 
 
Spinal cord injury above lumbosacral segments prevents voluntary and 
supraspinal control of voiding, initially leading to a hypotonic bladder followed by 
development of autonomic micturition and NDO mediated by spinal reflex 
pathways (de Groat and Yoshimura, 2006). Voiding can be complicated by 
detrusor sphincter dyssynergia (DSD), which is caused by simultaneous 
contraction of the bladder and the urethral sphincter due to lack of central 
coordination, resulting in post-micturition residual urine volumes.  
 
When these pathways are disconnected by spinal cord demyelinating plaques 
(MS) or injury, there emerge segmental reflexes which cause detrusor 
contractions in response to bladder distension. Animal experiments have shown 
activation of normally quiescent c-fibres following spinal cord injury, which 
become mechano-sensitive responding to bladder filling and stretch (de Groat 
and Yoshimura, 2006). 
 
Between 52-97% of patients with multiple sclerosis (MS) exhibit bladder 
symptoms and signs associated with spinal cord involvement (Litwiller et al., 
1999). Symptoms of frequency, urgency and nocturia are reported by both 
sexes, with incontinence reported more by women (Koldewijn et al., 1995). As 
described above, direct pathways project from the PMC to the sacral segments 
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of the cord (S2-S4), determining parasympathetic outflow to the detrusor as well 
as activity to the external urethral sphincter.  
 
Normally there is central inhibition of parasympathetic innervation to the 
detrusor, but in the absence of this, detrusor contractions are caused by sacral 
afferent activity causing synaptic activity in the sacral segment of the cord. This 
can give rise to the common urinary complaints of MS patients. As spinal cord 
involvement of MS increases, so does the worsening of bladder dysfunction 
(Betts et al., 1993), but it is rare to see upper urinary tract involvement 
(Koldewijn et al., 1995).  
 
However following traumatic spinal cord injury, most patients lose the reciprocal 
relationship between bladder and urethral sphincter function, resulting in 
detrusor sphincter dyssynergia (DSD). During bladder emptying, the urethral 
sphincter simultaneously contracts, causing bladder outflow obstruction. Up to 
half of patients with untreated DSD have high intravesical pressures, which in 
the long term may cause upper tract dilatation, reflux, progressive renal damage 
and failure (Hackler, 1977).  
 
There is accumulating recent evidence that aberrant afferent activity plays an 
important role in the pathogenesis of OAB and DO.  
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In the urothelium, studies have shown interstitial cystitis results in augmented 
ATP release which can cause painful sensation by exciting purinergic P2X 
receptors on sensory fibres (Sun et al., 2001; Birder et al., 2003). Increased 
basal urothelial levels of TRPV1 have been shown in human NDO (Apostolidis 
et al., 2005a).  
 
Various studies support the presence of suburothelial innervation expressing the 
capsaicin receptor TRPV1 (Brady et al., 2004b), purinergic receptor P2X3 
(Brady et al., 2004a), and the sensory neuropeptides substance P (SP) and 
CGRP (Smet et al., 1997) in the pathology of human DO. Patients with NDO 
and IDO were found to have increased TRPV1 and P2X3 suburothelial 
innervation compared to controls (Apostolidis et al., 2005b). Following BoNT/A 
treatment both receptors populations normalised to control levels. Intravesical 
instillations of the c-fibre toxin RTX were found to delay or suppress involuntary 
detrusor contractions in patients with IDO (Silva et al., 2002) and decrease 
TRPV1 and P2X3 immunoreactive fibres in NDO responders (Brady et al., 
2004a; Brady et al., 2004b). Women with IDO were found to have increased 
density of suburothelial SP and CGRP immunoreactive fibres compared to 
controls (Smet et al., 1997). Men with obstructive DO had an increased 
incidence of a positive ice water test, which is related to c-fibre afferent evoked 
bladder reflex (Chai et al., 1998). 
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 Autonomous bladder theory 
This theory suggests that the organisation of muscle regions in the bladder is 
modular, with circumscribed areas of muscle supplied by individual intramural 
bladder ganglia or by a node of interstitial cells, which collectively are termed 
the "myovesical plexus" (Drake et al., 2001). There is synchronisation between 
modules either through nerves, interstitial cells or direct communication via 
muscle cells. The theory suggests that during bladder filling there is 
autonomous activity with non-micturition contractions and phasic sensory 
discharges. This activity can shift in pathological conditions to more excitatory 
inputs with reduction of inhibitory inputs, leading to inappropriate augmentation 
of autonomous activity and to DO. Any factor enhancing communication 
between modules will predispose to detrusor overactivity. It is similar to the 
myogenic model but proposes that all structural and functional alterations 
associated with both increased filling sensation (urgency and frequency) and 
DO are summated and integrated peripherally, contributing to the overall level of 
excitation (Hashim and Abrams, 2007b). 
 
Functional MRI studies have suggested that inadequate activation of the frontal 
cortex may result in "poor bladder control", suggesting a central cause in the 
absence of overt neurological lesion (Griffiths et al., 2005).  
 
In summary, the pathophysiology in OAB and DO is controversial with various 
proposed theories. There are multiple disease processes with associated DO 
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and a large cohort of patients with idiopathic DO, but no single unifying patho-
physiological mechanism to explain causation.  
 
 Urotheliogenic theory 
This is based on changes occurring in the urothelium and suburothelium 
causing an increase the sensitivity in the suburothelial network of nerves and 
myofibroblasts resulting in enhanced spontaneous detrusor activity There are 
substantial signalling and sensory properties in the superficial layers of the 
bladder which have been noted to undergo upregulation in experimental 
detrusor overactivity. ATP and acetylcholine appear to be important 
neurotransmitters in sensory transduction. The important known constituents of 
the sensory pathway in the are documented on pages 36-49.  
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Chapter 2 - Detrusor Overactivity 
Detrusor Overactivity (DO) is defined by the ICS as “a urodynamic observation 
characterised by involuntary detrusor contractions during the filling phase which 
may be spontaneous or provoked” (Abrams et al., 2002). The Over-Active 
Bladder (OAB) syndrome is a symptom complex characterised by urgency, with 
or without urgency incontinence, usually accompanied by frequency and 
nocturia. Urinary urgency is a pathological sensation although defined as a 
“sudden compelling desire to void that is difficult to deter”, although there is 
much debate about the definition and translation of the word; especially defining 
the difference between the meaning of “strong urge” and “urgency”. OAB is 
based on clinical diagnosis while DO is based on involuntary detrusor 
contraction with reproduction of symptoms during the filling phase of 
urodynamics. The populations studied in the continence literature are quite 
varied, with conclusions applied to both OAB and DO populations. DO is further 
subdivided according to associated disease; when there is concurrent 
neurological disease, the condition is termed Neurogenic Detrusor Overactivity 
(NDO), and where the cause is unknown or undiagnosed it is labelled Idiopathic 
Detrusor Overactivity (IDO).  
 
Overactive Bladder Syndrome 
Population based estimates suggest that OAB affects 12-17% of adults in 
Europe and the United States (Milsom et al., 2001; Stewart et al., 2003; Irwin et 
al., 2006b), with significant negative effect on health related quality of life 
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(Coyne et al., 2004). Not all patients with OAB have DO and neither will all 
patients with DO have OAB, leading some authors to state that the bladder is 
not always a reliable witness (Hashim and Abrams, 2006). It was not until a few 
years ago that the prevalence of OAB was identified. Previous studies had 
looked at urinary incontinence but it was not until the standardisation of the 
definition of OAB that a large study be performed. In a review of 36 general 
population studies from 17 countries, the prevalence of urinary incontinence 
ranged from 5 to 69%, with most studies reporting a prevalence of any urinary 
incontinence in the range of 25–45% (Hunskaar et al., 2005). The recent EPIC 
study (Figure 7) of 19165 adult participants is the largest multinational (Canada, 
Germany, Italy, Sweden, and the United Kingdom) population based cross-
sectional survey and gives a good estimate of the prevalence of lower urinary 
tract symptoms using current ICS definitions (Irwin et al., 2006b). The 
prevalence of OAB was 11.8% (10.8% in men and 12.8% in women) and 
increased with age. Before the age of 60, it was more common in women than 
in men. In those with OAB, incontinence was present in 49.2% of women and 
28.7% of men. Disappointingly, there are virtually no population based studies 
of the prevalence of incontinence in developing countries (Milsom, 2009).  
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Figure 7: Prevalence of storage lower urinary tract symptoms by country and gender. UI = 
Urinary Incontinence. Reproduced from (Irwin et al., 2006b). 
 
Impact of incontinence 
OAB is a condition that causes a significant impact on all aspects of the quality 
of life (QoL) of an individual, including social, psychological, occupational, 
domestic, physical and sexual aspects (Brown et al., 2000a). One European 
cross-sectional population-based survey of 11 521 individuals, with 1272 
sufferers, showed 21% of OAB sufferers worried about interruptions to meetings 
and work because of frequent visits to the toilet, with 3% of sufferers needing to 
change jobs or becoming unemployed due to bladder control problems (Irwin et 
al., 2006a). 32% of sufferers felt depressed as a direct result of their symptoms, 
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and reported that these bladder symptoms were a source of great concern and 
made them feel uncomfortable in social situations. The associated incontinence 
made sufferers make decisions about voluntary or early retirement (27% men 
vs. 4% women). The additive effects of urgency combined with the fear of 
incontinence made sufferers shy away from participating in activities far from 
home and in situations involving people they know well, as well as those they do 
not know well.  Despite the debilitating effects of OAB symptoms, most 
individuals with OAB reported that their symptoms were something they had to 
learn to live with (74.3%). Just under half (43%) felt that their symptoms were 
not worth discussing with their doctor. These symptoms had a significant effect 
on the emotional well-being as well as the productivity of sufferers at home and 
at work. A study looking at health-related quality of life among adults with 
symptoms of overactive bladder showed that OAB had greater impact on QoL 
than diabetes (Figure 8) (Abrams et al., 2000). 
 
Elderly patients with OAB have an increased risk of urinary tract infections and 
visit the toilet more often, doubling the chance of becoming injured in a fall. 
Weekly or more frequent urgency incontinence was associated independently 
with an increased risk of falls and fractures in older women (Brown et al., 
2000b).  
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Figure 8: Comparison of Quality-of-Life Scores in Patients with OAB, Diabetes, and 
Normal Subjects. Source: Abrams P, Wein AJ. The Overactive Bladder: A Widespread But 
Treatable Condition Stockholm, Sweden: Erik Sparre Medical AB; 1998 
 
Nocturia can interfere with sleeping and rest, resulting in reduced energy, 
chronic fatigue and greater impairment of work and activity (Kobelt et al., 2003). 
In the elderly, this can lead to falls as alertness is impaired on waking and 
lighting is often at lower levels.  
 
Rates of depression and anxiety are increased in OAB with incontinence (Irwin 
et al., 2006a). OAB without incontinence causes anxiety, fear of incontinence, a 
sense of depression and hopelessness, all of which are worse for those with 
incontinence (Nicolson et al., 2007). 
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Cost consequence of OAB 
There is considerable economic burden to society from this disease. Direct 
costs include those of routine care, diagnosis, treatment and consequence 
costs. There are further indirect costs incurred from lost wages to patients and 
lost productivity as a result of morbidity and mortality. Intangible costs reflect the 
suffering and decreased QoL associated with the condition (Hu and Wagner, 
2000). An estimate of the economic costs of OAB in the United States in the 
year 2000 was $12.6 billion (Hu et al., 2003). Three quarters of this were spent 
in the community (female and male $7.37 and $1.79 billion respectively). This 
ranked fifth for cost after arthritis, pneumonia and osteoporosis (Hashim and 
Abrams, 2007b). 
 
In Europe, the direct cost of OAB in 2000 was estimated to be €4.2 billion 
affecting 20.2 million people over 40 across five European countries.  Average 
annual expenditure was estimated to be between €269 to €706 per patient, with 
the major cost being for containment (Reeves et al., 2006). OAB incurs a 
substantial direct cost that is anticipated to increase in the future in line with 
aging populations. 
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Clinical assessment of OAB 
OAB is a clinical diagnosis and is based on a history of frequency, urgency and 
nocturia with or without incontinence. The 3rd International Consultation on 
Incontinence 2004 defines the basic assessment necessary in the evaluation of 
OAB (Abrams et al., 2005). This includes a full history, a focused physical 
examination and appropriate investigations. The investigations should include a 
urinalysis ranging from dipstick to urine microscopy and culture to detect blood, 
glycosuria and occult infection. In addition, measurement of a post void residual 
using ultrasound or single "in and out" catheterisation, a frequency volume 
charge and QoL questionnaire are all recommended. Objective measurement of 
variables using uroflowmetry such as maximum flow rate and volume of residual 
urine after voiding gives useful information on micturition. Urinary tract 
ultrasound is also highly recommended if an anatomical cause is suspected. 
Urodynamic testing is recommended prior to invasive treatments, after 
treatment failure or in "complicated incontinence". The aim of the urodynamic 
evaluation is to assess bladder sensation, detect DO, assess urethral 
competence during filling, determine detrusor function during voiding, assess 
the outlet during voiding and to measure the residual urine. Visual inspection of 
the urethra and bladder by cysto-urethroscopy is important in patients with 
persistent dysuria or haematuria, as it can show mucosal abnormalities such as 
bladder tumours and strictures. 
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The frequency / volume chart should be kept for a minimum of 3 days in order to 
quantify the number of frequency episodes, the fluid input and output, estimate 
the functional capacity of the bladder and exclude polyuria (Dmochowski et al., 
2005).  
 
A disease specific OAB QoL questionnaire (e.g. ICIQ-OAB QOL) captures the 
severity of LUT symptoms and establishes a baseline from which treatments 
can be assessed. The National Institute for Health and Clinical Excellence 
(NICE) guidelines for the management of urinary incontinence in women 
suggest that incontinence should be categorised according to the patients‟ 
symptoms and treatment directed towards the predominant symptom (NICE, 
2006). The guidance further states that 3-day bladder diary assessment should 
be used. Urodynamics is not recommended routinely prior to conservative 
management.  
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Chapter 3 - Treatment of OAB / DO  
Treatments are based on clinical diagnosis with exclusion of other disease 
processes i.e. urinary tract infection, bladder tumour, calculi or diabetes mellitus.  
 
Conservative management 
When symptoms are mild, simple lifestyle interventions such as moderation of 
fluid intake to 1-1.5 litres a day and reduction of alcohol and caffeine can make 
a difference (Swithinbank et al., 2005), especially in the elderly. Patients are 
advised to avoid fluids four hours before bedtime, try reducing weight and cease 
smoking (Hannestad et al., 2003).  
 
Physiotherapy 
Behavioural therapy for DO was first reported in the 1960s advocating “voiding 
by the clock” (Jeffcoate and Francis, 1966). It is aimed at training the patient to 
re-learn cortical inhibition of detrusor contractions, thereby increasing voided 
volumes and the time interval between voids (Burgio, 2004). It requires high 
levels of motivation and encouragement. A systematic review in 2000 showed 
weak evidence that "bladder drill" (delaying micturition by progressively 
increasing intervals until a target of one void every 4 hours is met) is more 
effective than no treatment, and weak evidence that bladder drill is better than 
drug (oxybutynin IR, flavoxate and imipramine) treatment (Berghmans et al., 
2000). Bladder training is usually supplemented by pelvic floor exercises. 
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Patients are taught to tighten the pelvic floor when they sense an involuntary 
contraction. There is evidence that this can potentiate the guarding reflex, 
inhibiting detrusor contraction. 
 
NICE recommends offering patients bladder training for a minimum of 6 weeks 
as first line treatment of OAB (NICE, 2006). Further well designed trials are 
required to determine the effect of bladder retraining and pelvic floor exercises, 
as current studies in this area remain very heterogenous in type of therapy and 
populations studied.  
 
Antimuscarinic agents 
It is generally accepted that activation of muscarinic receptors on the detrusor is 
one of the mechanisms driving abnormal detrusor overactivity in the diseased 
bladder (de Groat, 1997). Regardless of the precise locus of action of 
antimuscarinic drugs (i.e. afferent or efferent), their widespread use for the 
treatment of OAB over the past three decades underscores the critical role of 
muscarinic receptors in the pathophysiology of this disorder.  
 
Antimuscarinics include oxybutynin, tolterodine, solifenacin, trospium chloride, 
propiverine and fesoterodine (table 1).  
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Table 1: Current UK licensed antimuscarinic medications 
Generic 
Name 
Trade 
Name ® 
Dose 
(mg) 
Frequenc
y 
Receptor 
subtype 
selectivity 
Eliminatio
n half life 
(hours) 
Tolterodine 
tartrate 
 
Detrusitol 2 BD Non-selective 2.4 
Tolterodine 
tartrate XL 
 
Detrusitol 
XL 
4 OD Non-selective 8.4 
Trospium 
chloride 
 
Regurin 20 BD Non-selective  
 
20 
Trospium 
chloride 
 XL 
 
Regurin XL 60 OD Non-selective  38.5 
Oxybutynin 
chloride 
 
 2.5 - 5 BD-QDS Non-selective 2.3 
Oxybutynin 
chloride XL 
 
Lyrinel XL 5 - 30 OD Non-selective 13.2 
Oxybutynin 
Transdermal 
 
Kentera 3.9 / 24 
hours 
Twice 
weekly 
Non-selective 8 
Propiverine 
hydrochloride 
 
Detrunorm 15 OD-QDS Non-selective 4.1 
Darifenacin Emselex 7.5 - 15 OD Selective M3 
receptor 
antagonist 
 
3.1 
Solifenacin Vesicare 5 - 10 OD Selective 
M2/M3 
antagonist 
 
40 – 68  
 
Fesoterodine Toviaz 4-8 OD Non-selective 6 - 9 
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Antimuscarinic mechanisms of action 
This class of drugs blocks muscarinic receptors with variable selectivity. Until a 
few years ago, the received wisdom was that antimuscarinic drugs act by 
blocking the detrusor muscarinic receptors which are stimulated by the release 
of acetylcholine (ACh) from the parasympathetic, cholinergic innervation. 
However this traditional view was challenged when, based on the observation 
that they act mainly during the storage phase decreasing symptoms of urgency 
and increasing bladder capacity, it was proposed their action was predominantly 
on afferents (Andersson, 2003, 2004). 
 
There is good experimental evidence that antimuscarinics act on the storage 
phase by decreasing afferent nerve (Aδ and c fibre) activity (De Laet et al., 
2006; Iijima et al., 2007; Daly et al., 2010). The antimuscarinic drugs are all 
competitive antagonists, and during micturition where there is a large release of 
ACh the effect of the antimuscarinic drug would be overcome by endogenous 
agonist. If the sole effect of antimuscarinics were to be on the efferent pathway, 
we should clinically observe decrease in voiding efficiency. Although large 
doses of antimuscarinics can cause urinary retention, in the dose ranges used 
for OAB / DO, there is little evidence for increased residual volumes, (Finney et 
al., 2006).  
 
Yokoyama et al. administered intravenous and intravesical tolterodine to rats 
with DO induced by cerebral artery occlusion, with and without RTX (an 
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analogue of capsaicin which induces c-fibre afferent de-sensitisation) 
(Yokoyama et al., 2005). Tolterodine increased bladder capacity at lower doses 
in untreated rats, but was ineffective in those treated with RTX. The authors 
suggest that the afferent nerves (Aδ and C-fibres) are fundamental to 
antimuscarinic mode of action.  
 
Systemic oxybutynin (De Laet et al., 2006) and darifenacin (Iijima et al., 2007) 
have been shown to reduce bladder afferent activity mediated by both Aδ and c-
fibres in pelvic nerve studies in rats. The inhibitory effect of darifenacin was 
more pronounced on c-fibre as compared to oxybutynin, which affected both 
types of fibres. Both these studies suggest that antimuscarinics directly or 
indirectly influence bladder sensory nerves, inhibiting the afferent part of the 
micturition reflex. Conversely, muscarinic agonists have also been shown to 
significantly inhibit the afferent response to bladder distension in wild type mice 
(Daly et al., 2010).  
 
In healthy women, tolterodine has been shown to increase the sensory 
threshold to electrical stimulation of the bladder, which the authors here 
speculated could be due to tolterodine 's effect on the suburothelium (Boy et al., 
2007). 
 
Muscarinic receptors are found on bladder urothelial and suburothelial cells 
(Mukerji et al., 2006; Birder and de Groat, 2007). There is release of ACh in 
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response to stretch from the urothelium and suburothelium (Yoshida et al., 
2006; Yoshida et al., 2008). A significant increase in suburothelial cell M2 and 
M3 receptor immunoreactivity has been found in human IDO compared to 
controls (Mukerji et al., 2006). It has been postulated that it is a combination of 
ACh and Adenosine 5'-triphosphate (ATP) released during the storage phase 
has an excitatory effect on nerves in the suburothelium and the detrusor and 
which give rise to bladder afferent activity (Andersson et al., 2009). These 
experimental observations all point to the conclusion that the urothelium and 
suburothelium muscarinic receptors may be the key therapeutic target of 
antimuscarinic drugs.  
 
Clinical efficacy  
All the above antimuscarinics (Table 1) have evidence to support their efficacy 
in the treatment of DO and OAB. Large scale, randomised, placebo controlled 
studies have shown significant reductions in urinary frequency, urgency 
episodes, and Urgency Urinary Incontinence (UUI) episodes (Herbison et al., 
2003; Chapple et al., 2005).  
 
The clinical relevance of the efficacy of antimuscarinic drugs was questioned by 
the Herbison's systematic review in 2003, with the conclusion that although they 
produce statistically significant improvements over placebo, the benefits are of 
limited clinical significance (Herbison et al., 2003). Larger, more recent meta-
analyses have refuted this view by including currently used drugs, showing that 
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this class of drugs are of clinically significant benefit (Chapple et al., 2005; 
Chapple et al., 2008a; Novara et al., 2008).  
 
Chapple's 2005 systematic review attempted to address the criticisms of the 
Herbison review by looking at quality of life data in included trials and attempted 
to 'split' different drugs to assess any variation between the different drugs 
(Chapple et al., 2005). The review conclusions suggested that antimuscarinics 
were efficacious, safe and well tolerated, with marked improvements in quality 
of life. There were more trials included in this study with active comparator 
studies also allowed. The study criticised the quality of reporting in the studies, 
minimal data on older patients and limited quality of life data. Oxybutynin 
Immediate Release (IR) was found to be least tolerable and associated 
consistently with greater adverse events. The systematic review found that that 
population studied was very restrictive and not reflective of daily clinical 
practice. Few trials looked at older patients (>65 years) and at patients with 
NDO.  
 
An update in 2008 looked at 73 blinded, randomised placebo and active 
controlled trials of oral and transdermal antimuscarinics to treat OAB (from over 
12,000 references) (Chapple et al., 2008a). Antimuscarinics were found to be 
more effective than placebo, with good tolerability. The mean change with 
anticholinergic medication was between 0.4 to 1.1 incontinence episodes per 
day. There were no statistically significant differences for efficacy among 
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treatments in meta-analyses of active controlled trials. All drugs were well 
tolerated but oxybutynin IR was associated with the highest risk of trial 
withdrawal. Tolterodine 2mg IR and Oxybutynin Transdermal System were 
associated with adverse events similar to placebo, the other agents 
(Fesoterodine, Solifenacin, Propiverine IR and Extended Release [ER], 
Oxybutynin IR and ER, Trospium IR) had an adverse event profile greater than 
that of placebo. Dry mouth was the most common adverse event, others being 
constipation, pruritus and headache. The newer drugs allowed dose flexibility 
and titration of medication depending on efficacy and tolerability. This study 
again highlighted the limited evidence available in elderly patients with 
significant co-morbidity. There was very limited data on CNS adverse events, 
such as memory impairment. The conclusions were that this group of drugs was 
efficacious, safe and well tolerated, with improved Health Related Quality of Life 
(Chapple et al., 2008a).  
 
Novara et al (2008) reviewed 50 Randomised Controlled Trials (RCT) and three 
pooled analyses to evaluate the efficacy and safety of antimuscarinics. They 
concluded that the trials had good methodological quality showing efficacy of 
antimuscarinics, that extended release were preferable to immediate release 
agents and the transdermal route of administration did not confer a significant 
advantage over the oral route due to local site reactions (Novara et al., 2008). 
Few studies did long-term follow-up of patients with patient reported outcomes. 
The authors pointed out that the majority of studies were designed to reflect the 
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needs of the company for registration rather than address the question relevant 
for clinical practice, which is fair criticism of industry funded trials. However, the 
finance required to sponsor such large expensive large-scale trials is beyond 
the scope of independent researchers. Further independent comparative clinical 
studies are required. 
 
 
Onset of action 
The onset of action of antimuscarinics can be quite variable. Tolterodine ER in 
an open labelled study reduced micturitions, urgency and UUI episodes as early 
as on day 5 of treatment (Sussman et al., 2007). Darifenacin significantly 
reduced similar parameters in patients with OAB at 2 weeks of treatment (Haab 
et al., 2004), whereas patients taking trospium showed improvements in UUI 
and urgency episodes  as early as on days 1 to 5 (Landis et al., 2004).  
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Figure 9: Antimuscarinic agents. Note the structural differences between tertiary (all 
except trospium) and quaternary (trospium) amines. Reproduced from Abrams P & 
Andersson KE Muscarinic receptor antagonists for overactive bladder. BJU 
International 100 (5), 987-1006. 
 
Pharmacokinetics 
Antimuscarinic drugs (Figure 9) are divided into tertiary and quaternary amines 
and they impart the pharmacokinetics of the molecule. Tertiary amines have no 
ionic charge, are lipophilic and more readily absorbed through the 
gastrointestinal tract, as well as cross the blood brain barrier easily. In contrast, 
positively charged quaternary amines i.e. trospium chloride are hydrophilic and 
do not easily pass into the brain (Pak et al., 2003), but still produce peripheral 
antimuscarinic effects. Tertiary amines undergo significant cytochrome P450 
metabolism, whereas trospium has little enzyme metabolism, with the vast 
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majority excreted in the urine unchanged compared to oxybutynin or tolterodine; 
reducing the potential for drug interaction.  
 
Drug delivery 
The vast majority of antimuscarinic drugs are oral agents, however they have 
been used intravesically and transdermally. Extended release formulations have 
been licensed and prolong the duration of release of active drug, allowing once 
daily administration. Currently only oxybutynin is licensed as a transdermal 
sustained delivery patch, which allows for more stable serum concentrations 
and avoids first pass hepatic metabolism (Bang et al., 2003).  
 
Tolerability and safety 
Antimuscarinic agents block acetylcholine binding at many subtypes of 
muscarinic receptor not just in the bladder but in other organ systems, leading to 
adverse effects. Blockade of M3 receptors in the salivary gland, lower bowel and 
ciliary smooth muscle are consistent with the mechanism of action of 
antimuscarinics and give rise to the most widely reported side effects of dry 
mouth, constipation and blurred vision. Transdermal formulation of oxybutynin 
avoids first pass metabolism and the formation of the active metabolite N-
desethlyoxybutynin, which has greater affinity for parotid gland muscarinic 
receptors, resulting in a much reduced rate (94% vs. 34%) of dry mouth in RCTs 
comparing immediate release oxybutynin with the transdermal formulation 
(Davila et al., 2001). 
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Elderly patients account for a large number of OAB patients; they are more 
susceptible to cognitive effects and constipation, both of which can further 
exacerbate urinary symptoms. 
  
Although most studies state low withdrawal rates from adverse effects, in clinical 
practice, patients do complain of the side-effects. Although these may be 
tolerated for short periods similar to the follow-up reported in trials, in the long 
term many patients discontinue their treatments. Antimuscarinics are not 
optimum agents for OAB and DO given their limited efficacy and non-selectivity, 
but they are currently the first line drugs of choice, due to limited alternative oral 
agents.  
 
Alternate classes of drugs 
Alternative pharmaceutical classes of drugs used to treat OAB symptoms with 
placebo controlled trial evidence include desmopressin and duloxetine (Hashim 
and Abrams, 2007a; Steers et al., 2007). Nicorandil, a potassium channel 
opener together with a nitric oxide donor has been tried in animal models, with 
results showing suppression of DO in neurogenic and myogenic models 
(Kamiyama et al., 2008). 
 
Another drug class showing promise are the beta 3 adrenoceptor agonists 
which promote bladder relaxation. It has been shown in dog models that these 
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agonists cause detrusor relaxation as well as increases in the micturition reflex 
threshold (Hicks et al., 2007). 
 
In-vitro studies have shown that non-selective β-adrenoreceptor agonists like 
isoprenaline have a pronounced inhibitory effect on human bladder, causing 
increases in bladder capacity (Anderson, 1993). This has not been followed up 
as a therapeutic option because of probable cardiac side effects. Subtypes of 
the β-adrenoreceptor (β-AR) have been identified both in the detrusor and in the 
urothelium (Michel and Vrydag, 2006; Otsuka et al., 2008), with evidence that 
these are functionally active (Leon et al., 2008). RT-PCR experiments have 
identified β3-AR as being predominantly expressed in human detrusor (Michel 
and Vrydag, 2006). It is thought that β-AR causes relaxation of the detrusor by 
activation of adenylyl cyclase together with formation of cAMP (Frazier et al., 
2008). Animal in-vivo studies have shown that β3-AR agonists increase bladder 
capacity without affecting voiding parameters (Kaidoh et al., 2002; Takeda et al., 
2002). 
 
Two current β3-AR agonists are being evaluated in human studies as treatment 
in DO: solabegron (GW427353) and mirabegron (YM178) (Drake, 2008). 
Reporting in abstract form by Chapple et al. showed primary efficacy by 
significant reduction in mean micturition frequency with mirabegron compared to 
placebo (Chapple et al., 2008b). Secondary variables included significant 
improvements in mean volume per micturition, mean number of incontinence 
episodes, nocturia episodes and urgency incontinence episodes. This study 
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demonstrates the proof of principle of β-AR agonists being useful agents in 
symptoms of OAB and paves the way for further large randomised controlled 
trials. 
 
Recently Cizolirtine citrate (cizolirtine), an inhibitor of CGRP and Substance P 
release has been shown to be efficacious compared to placebo in a phase 2 
proof of concept study (Zat'ura et al., 2009). 
 
Sacral Nerve Stimulation (SNS)  
Sacral nerve stimulation or neuromodulation is recommended by NICE for 
women who have DO refractory to conservative and medical therapy (NICE, 
2006). It involves the stimulation of the S3 nerve root by an Implantable Pulse 
Generator (IPG) (Interstim® and Interstim II®, Medtronic Inc, Minnesota, 
Minneapolis, USA), and has been shown to reduce episodes of frequency, 
urgency and urgency incontinence. It is an expensive treatment costing £7,000 
for the implant alone and requires expert assessment and management, 
especially where there are complications. The exact mechanism of action is 
unknown but theories postulate that both afferent and efferent mechanisms may 
be involved.  
 
In long term case series studies, symptom improvement was observed in about 
50% of patients with frequency and urgency (Table 2). Patients with 
incontinence have similar reported efficacy, however a lot of studies report 
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improvements rather than measureable objective indicators. The original 
Interstim® IPG lasted approximately 7 years, needing to be replaced with a new 
unit, which normally sits in a subcutaneous pocket either in the buttock or the 
abdomen. The new Interstim II® IPG system is smaller, with fewer connectors 
but also with a reduced battery life. 
 
In long term series, over half the women implanted suffered a complication such 
as infection, box site pain, lead migration or leg pain, with most remedied with 
medication or surgery (Datta et al., 2008). There is hope that the new two stage 
implantation will improve the efficacy, reduce the number of complications and 
successfully treat more patients.  
 
Posterior Tibial Nerve Stimulation (PTNS) 
PTNS is second line therapy for OAB syndrome that is approved by NICE. It is 
administered by placement of a fine gauge needle adjacent to the tibial nerve 
just above the ankle. This is connected to a low voltage stimulator. The 
mechanism of action is unknown but is thought to be by neuromodulation of the 
sacral nerve plexus. Treatment involves 12 sessions lasting 30 minutes each 
usually performed weekly. Further sessions are required to maintain efficacy. 
Two randomised clinical trials compared PTNS to placebo or  anticholinergics 
have demonstrated moderate/marked improvement in 55% and 80% of patients 
respectively with significant improvements in quality of life (Peters et al., 2009; 
Peters et al., 2010). There are no major safety issue with treatment. 
 
82 
Table 2 : Published reports of efficacy of Sacral Neuromodulation in Urgency 
Incontinence (UI) and Urgency Frequency (U/F).  
Study Total  Patients 
with UI 
 Patients 
with U/F 
 Follow-
up 
  Cured >50% 
improvement 
Improved >50% 
improvement 
Improved  
US Patient 
Registry 
(Pettit et 
al., 2002) 
81  27/43  10/19   
        
(Amundsen 
and 
Webster, 
2002) 
12 2/12 12/12    7.8 
months 
        
(Bosch and 
Groen, 
2000) 
45  27/45 9/45   47.1 
months 
        
(Siegel et 
al., 2000) 
112  21/41 19/41 16/29 5/29 24-36 
months 
        
(Schmidt et 
al., 1999) 
34 16/34 10/34 26/34   6 
months 
        
(Hassouna 
et al., 2000) 
25    14/25  24 
months 
        
(Elhilali et 
al., 2005) 
   1/6  10/22 77.4 
months 
        
(van 
Voskuilen 
et al., 2006) 
149   89/107   70 
months 
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Surgery 
Clam augmentation cystoplasty 
The principle of bladder augmentation is to increase bladder capacity and 
compliance and to decrease overactivity. It is performed by isolating a de-
tubularised segment of intestine segment (most commonly ileum) and suturing it 
to the top of a bi-valved bladder. It is a procedure indicated in patients with low 
capacity bladder who are refractory to all therapies, and whose quality of life is 
severely hampered. It results in improvements in symptoms and bladder 
capacity plus reductions in maximum detrusor pressures in spinal cord injured 
patients (Khastgir et al., 2003). However, it fails to resolve OAB symptoms in 
approximately 8% of patients with NDO and 40% of patients with IDO 
(Greenwell et al., 2001). The complications of the procedure are that patients 
often have to self-catheterise, have problems with mucus retention, stones and 
a 5% long-term risk of adenocarcinoma if large bowel is used. If ileum is used 
for augmentation, there are further risks of hyperchloraemic acidosis, vitamin 
B12 and folate malabsorption. The most dreaded complication is spontaneous 
perforation, which carries a mortality of about 25%. 
 
Urinary diversion  
In patients with severe detrusor overactivity who cannot or will not manage 
clean intermittent catheterisation, an option is to perform a urinary diversion. 
Urine then drains into an ileal conduit, which is attached to the abdominal wall 
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as a stoma. The urine then  collects into an appliance bag. If a cystectomy is not 
simultaneously performed, there are long-term risks of bladder cancer, pyocystis 
and spasticity.  
 
More complex continent diversions such as Mitrofanoff and Koch pouches can 
be reconstructed if patients are willing to catheterise an opening in the 
abdominal wall. There is a high revision rate for continent catheterisable 
vesicostomy, mainly for stomal stenosis or difficulty in catheterisation (Van der 
Aa et al., 2009). The risk of complications and the irreversibility necessitate that 
surgery remains the option of last resort in the management of detrusor 
overactivity.  
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Botulinum toxin in detrusor overactivity 
Rationale for use of BoNT/A in OAB and DO 
There are significant limitations of antimuscarinic medication and surgical 
procedures with their high incidence of side effects. Intermediate treatments that 
fill the gap between oral medication and bladder surgery have failed to produce 
robust clinical results. Intravesical instilled neurotoxins, namely capsaicin and 
RTX, remain unlicensed 15 years after their introduction, with conflicting results 
of efficacy in randomised placebo controlled trials (Silva et al., 2005; Rios et al., 
2007). Sacral neuromodulation is an invasive and costly procedure involving 
significant complications and limited only for IDO patients. A serious alternative 
treatment was lacking until the turn of the last century.  
 
Since ACh is the main neurotransmitter involved in detrusor contraction, it was 
thought that suppressing its release in DO with BoNT/A, a toxin known to inhibit 
Ach release, would be of clinical benefit.  
Botulinum neurotoxin type A (BoNT/A) 
The botulinum toxins are among the most potent toxins known, and were first 
identified in 1897 as the product of the gram positive anaerobe Clostridium 
botulinum, the causative agent for botulism food poisoning (Schantz and 
Johnson, 1997). Although all serotypes block transmission at the neuromuscular 
junction, thereby reducing muscle activity to varying degrees, BoNT/A has the 
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most prolonged effect and has been studied extensively, especially in striated 
muscle. 
 
BoNT/A has been approved for use in various conditions of excess skeletal 
muscle contractility (e.g. cervical dystonia, blepharospasm and limb spasticity) 
and oversecretion of sweat (hyperhidrosis). Its efficacy in disorders such as 
oesophageal spasm and DO have prompted some observers to note that its 
effect in smooth muscle is similar to skeletal muscle, but with a longer duration 
of action. (Storr et al., 2001).  
 
Molecular basis of BoNT activity 
Seven immunologically distinct serotypes of this neurotoxin exist (designated A 
to G). BoNT/A is synthesised as a single-chain polypeptide of 150 kDa 
molecular mass, consisting of 1285 amino acids (Lacy et al., 1998). The toxin 
associates with additional non-toxic proteins to form larger molecules of 
between 300 – 900 kDa. When the single chain is cleaved by an endogenous 
clostridial protease to a 100 kDa heavy chain and a 50 kDa active light chain, 
maximum biological activity is gained (Simpson, 2004). The two chains are still 
linked by disulphide and non-covalent interactions (Kozaki et al., 1989). 
 
BoNT/A is folded into three functional domains that directly affect the toxin‟s 
action on the target cell. The domains work together via three stages: (i) binding 
and internalisation, (ii) translocation and (iii) exocytosis inhibition (Figure 10). 
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The c-terminal of the heavy chain binds to ecto-acceptors on the pre-synaptic 
cholinergic nerve terminal and is taken up into neurones by endocytosis (Dolly 
et al., 1984; Black and Dolly, 1986). BoNT/A enters neurons by binding to the 
synaptic vesicle protein SV2, the expression of which is enhanced by synaptic 
activity (Dong et al., 2006).  
 
Once internalised and present within a vesicle, BoNT/A undergoes a pH-
dependent conformational change which causes disassociation of the light and 
heavy chains (Li and Singh, 2000). The heavy chain forms a pore in the vesicle 
by inducing a conformational change, allowing the light chain to enter the 
cytoplasm and function as a zinc dependent protease, targeted specifically 
towards SNARE (Soluble N-ethylmaleimide-sensitive fusion Attachment protein 
Receptor) proteins which mediate fusion of cellular transport vesicles with cell 
membranes (Schiavo et al., 1992b; Schiavo et al., 1992a). 
  
The light chains of the different serotypes act to disable the vesicle docking 
system of exocytosis by cleaving different SNARE components. BoNT/A 
cleaves SNAP-25 by removing 9 amino acids from the C-terminus, whereas 
BoNT/E cleaves 26 amino acids (Dolly, 2003). The cleavage by BoNT/A is 
highly specific as it recognises a highly conserved, nine-residue binding motif 
that occurs with the SNAP-25 protein (Washbourne et al., 1997). The other toxin 
serotypes cleave syntaxin and synaptobrevin at various other locations.  
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Figure 10: Three-dimensional structure of botulinum neurotoxin type A (BoNT/A). The 
binding domain regions in the C-terminal of the heavy chain, are indicated in red and 
yellow. The translocation domain in the N-terminal of the heavy chain (green) contains 2 
parallel helices, whereas the toxic moiety (blue) resides in the light chain which 
possesses the protease with zinc (lilac dot) bound at the active site. Reproduced from 
Dolly (Dolly, 2003). 
 
BoNT/A has the greatest stability of proteolytic activity when compared to other 
subtypes of toxin, with activity for over 31 days in cerebellar granular neurones. 
BoNT/C1 showed activity for 25 days, BoNT/B for 10 days and BoNT E for 0.8 
days (Foran et al., 2003). The cleavage product of SNAP-25 is SNAP-25A, 
which is also antagonistic and inhibitory to the function of unproteolysed SNAP-
25 (O'Sullivan et al., 1999). These properties make BoNT/A ideally suited to 
clinical use for long-term inhibition of neurotransmitter release (Dolly and Aoki, 
2006). Recovery of cholinergic neurotransmission in striated muscle is 
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dependent on the removal of the BoNT/A light chain protease and restoration of 
intact SNARE proteins (Foran et al., 2003).  
 
 
Figure 11: Inhibition of acetylcholine exocytosis by BoNT/A. (A/B = Docking of vesicle to 
synaptic cleft; C = Membrane fusion and Ach released. D= BoNT/A binds to SV2 and 
enters by endocytosis; E= Light Chain released into cytosol by conformational change in 
heavy chain; F= Light Chain of BoNT/A cleaves SNAP-25 preventing assembly of SNARE 
complex and further blocking Ach release. Reproduced from Nat Clin Pract Urol. (2008) 
Drug Insight: biological effects of botulinum toxin A in the lower urinary tract (Chancellor 
et al., 2008).  
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Action on striated versus smooth muscle 
In striated muscle, BoNT/A temporarily inactivates neurotransmission and acts 
as a biochemical neuromodulator. It blocks the signalling between α and γ motor 
neurones and extrafusal muscle fibres and spindles (Rosales et al., 1996). Cells 
show temporary signs of denervation with central mitochondria dispersed to the 
periphery within a few weeks of injection (Borodic and Ferrante, 1992). The 
physiological changes include reduction in the resting membrane potential as 
well as elimination of extra-junctional acetylcholinesterase activity (Thesleff et 
al., 1990). There is compensatory sprouting and growth of extra-junctional motor 
nerve terminals which are rich in dense core vesicles (de Paiva et al., 1999). 
Once there is return of vesicle turnover to the original parent terminals, there is 
elimination of the superfluous sprouts.  
 
Comparatively in detrusor smooth muscle there is no evidence of nerve 
sprouting in detrusor muscle following BoNT/A (Haferkamp et al., 2004). 
BoNT/A injections do not appear to be producing significant inflammatory 
changes, fibrosis, or dysplastic changes in human bladder 
urothelium/suburothelium after a single injection (Apostolidis et al., 2008). NDO 
patients treated with BoNT/A had less bladder wall fibrosis then those not 
treated (Comperat et al., 2006). There was no evidence of apoptosis following 
the 1st injection of BoNT/A in human detrusor (Kessler et al., 2009).  
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Clinical data from intradetrusor BoNT/A 
The first publication of the use of intra-detrusor BoNT/A injection was in 1999 
(Stohrer et al., 1999) and was followed by several open labelled studies 
confirming impressive clinical results in patients with spinal cord injury and 
NDO. These papers all described improvements in clinically measurable 
urodynamic parameters such as bladder capacity, volume at first contraction, 
decreases in detrusor pressure during filling, as well as patient reported 
parameters such as frequency and urgency incontinence (Schurch et al., 2000; 
Popat et al., 2005; Schurch et al., 2005). In 200 spinal NDO patients, continence 
was restored in 73%, with results lasting up to 9 months following a single 
BoNT/A injection (Reitz et al., 2004). A further American study of 42 patients 
with OAB of various aetiologies (NDO, IDO, sensory urgency and interstitial 
cystitis) had return to continence in 81% of the study population with sustained 
results to 6 months (Smith et al., 2005).  
Preparations  
The most common serotype of BoNT is BoNT/A which was licensed under the 
brand name of Botox® (Allergan Inc., Irvine, CA, USA). Another commercially 
available form of BoNT/A is Dysport® (Ipsen Ltd., Slough, Berkshire, UK), which 
has different associated proteins. Both products have different dosage, efficacy 
and safety profiles and should not be considered as bioequivalent (Table 3) 
(Wenzel et al., 2007). There is inevitable commercial rivalry about the 
bioequivalence of the two preparations, however the majority of the clinical trials 
of the bladder have used the Allergan Botox® preparation.  
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The recently released BoNT/B products Myobloc® and Neurobloc® (Solstice 
Neurosciences Inc, San Francisco, CA) are not clinically equivalent with BoNT/A 
products, as they have very different product characteristics and have been 
noted to have systemic antimuscarinic adverse effects (Dressler and Eleopra, 
2006; Ghei et al., 2006) 
 
Table 3 : Comparison of Botox and Dysport characteristics 
 
 
Dysport® Botox® 
 
Complex molecular weight (kDa) 500–900 900 
Units/package 500 100 
Neurotoxin protein content (ng/vial) 4.35 c. 5 
Formulation Lyophilized Vacuum dried 
pH c. 7·0 c. 7·0 
Excipient HA with lactose HA with 0·9% NaCl 
Target SNAP-25 SNAP-25 
Approval 1989 (US) 1991 (EU) 
 
Table modified from (Wenzel et al., 2007) with data from (Pickett et al., 2007) 
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Randomised controlled trials (RCTs) 
In a placebo controlled randomised double blind trial studying two different 
BoNT/A doses (200U and 300U BOTOX®) versus placebo, Schurch et al 
demonstrated significant improvements in incontinence episodes, frequency and 
urodynamic variables only in the toxin-treated groups. The placebo-treated 
group failed to demonstrate improvements in any of the study outcomes up to 
24 weeks post-treatment. Results were highly significant despite the small 
numbers of patients recruited (19 patients in each toxin group, 21 patients in the 
placebo group) (Schurch et al., 2005).  
 
In IDO patients, there have been comparable urodynamic and symptomatic 
improvements to those found in NDO patients (Kessler et al., 2005; Popat et al., 
2005). The largest IDO series of 100 patients showed low dose (100U Botox®) 
BoNT/A restored continence in 86% of patients, with normalisation of frequency 
within 1-2 weeks and a mean duration of response of 6 months (Schmid et al., 
2006).  
 
A single centre, randomised double-blind, placebo controlled trial in 16 patients 
with IDO and 18 placebo controls demonstrated 200 U (Botox®) improved 
frequency, urgency and urgency incontinence episodes at 4 and 12 weeks after 
BoNT/A injection (Sahai et al., 2007). Urodynamic investigations demonstrated 
an increase in mean final cystometric capacity of 145ml compared to placebo, 
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with improvements sustained out to six months.  Six patients were required to 
perform CISC due to high residual volumes. Significant improvements in QoL 
outcome measures were also observed in this study following BoNT/A.  
 
A head to head prospective RCT of BoNT/A and intravesical RTX in spinal NDO 
patients showed superior efficacy of BoNT/A in clinical and urodynamic study 
endpoints at 6, 12 and 18 month follow-up (Giannantoni et al., 2004).  
 
Botulinum neurotoxin type B (BoNT/B) has also showed efficacy in a 
randomised, double blind, placebo controlled crossover trial in a mixed 
population of 3 NDO and 17 IDO patients. BoNT/B improved bladder capacity, 
frequency, incontinence and  QoL but its effect lasted about 6 weeks, much less 
than the duration of BoNT/A (Ghei et al., 2005). 
 
Onset and duration of effect 
Patients report improvements soon after the treatment. A study looking at daily 
changes occurring in the first week after bladder BoNT/A injections in a group of 
29 patients with DO showed decline in urgency, frequency and nocturia at day 
2, followed by a reduction in incontinence episodes at day 3 (Kalsi et al., 2007). 
This was confirmed in a larger study of 100 patients with a mean time to loss of 
urgency of 5 days, sustained at 4 weeks in 82% of patients (Schmid et al., 
2006). 
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The largest studies of Botox® in 200 patients showed a mean duration of action 
of between 9 and 11 months, with repeat injections showing equally sustained 
beneficial effect (Reitz et al., 2004; Grosse et al., 2005). A cohort study showed 
similar results, in that the mean time to symptom return was 10.4 months (Popat 
et al., 2005). Differences in dose, injection technique, formulation of BoNT/A, 
volume of diluent and number of injection sites may play a role in the variability 
of effect in different patients.  
 
Evidence for an effect of BoNT/A on afferent pathways 
In the bladder, the action of BoNT/A was initially thought to be via inhibition of 
presynaptic vesicular Ach release through the cleavage of synaptosomal-
associated protein of 25kDa (SNAP-25), inducing detrusor muscle relaxation 
(Schurch et al., 2000). However, BoNT/A also has an inhibitory effect on 
SNARE dependent expression and vesicular release of other neuropeptides, 
neurotransmitters and receptors mediating sensory neurotransmission. BoNT/A 
has been shown to induce long lasting inhibition of SP following cleavage of 
SNAP-25 (Welch et al., 2000) as well as release of glutamate in a model of 
inflammatory pain (Cui et al., 2004). Other studies have shown BoNT/A 
inhibition of exocytosis of TRPV1
 receptors to the plasma membrane (Morenilla-
Palao et al., 2004),  
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Additional studies in a rat pain model have demonstrated inhibition of CGRP 
release from superficial layers in the bladder, together with an increase in the 
interval between bladder contractions (Chuang et al., 2004). 
 
BoNT/A effect on afferent bladder pathways 
In rat models of NDO, BoNT/A significantly reduced the abnormal distension 
evoked urothelial release of ATP (Khera et al., 2004) and the contractions 
evoked by application of ATP or capsaicin to rat bladders in-vivo (Atiemo et al., 
2005).  
 
Biopsies taken from patients with IDO and NDO before and after BoNT/A 
showed a progressive decrease with normalisation in sub-urothelial P2X3
 and 
TRPV1 receptor immunoreactivity indicating that BoNT/A affected sensory 
afferents in this layer. Changes in P2X3 receptors coincided with clinical 
improvements in patient reported episodes of urgency (Apostolidis et al., 
2005b).  
 
Further supporting evidence comes from a study which looked at homogenised 
bladder tissue levels of Nerve Growth Factor (NGF) in patients with NDO; these 
were reported to be significantly reduced up to 3 months after treatment with 
BoNT/A, suggesting that BoNT/A can modulate the production or release of 
NGF from the bladder (Giannantoni et al., 2006). A follow-on study looked at 
urinary levels of NGF and found that it was increased in patients with NDO and 
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IDO, however following successful treatment with BoNT/A these decreased 
significantly towards control levels. The authors concluded that NGF was a 
sensitive biomarker for DO and could be used to evaluate successful treatment 
after BoNT/A (Liu et al., 2008) and antimuscarinic therapy (Liu et al., 2009). 
 
 
BoNT/A effect on efferent bladder pathways 
Although BoNT/A is proposed to exert its therapeutic effect on patient symptoms 
via an effect on the afferent pathway, it does also elicit changes in the efferent 
pathway of bladder contraction. Electrical field stimulation experiments designed 
to mimic parasympathetic nerve overactivity in DO have demonstrated 
decreases in the neuronal release of Ach in bladder strips treated with BoNT/A 
compared to sham treated animals (Smith et al., 2003). 
 
Clinical studies have also demonstrated post-BoNT/A decreases in detrusor 
pressures in both filling and voiding phases, as well as increases in post-void 
residual volumes (Popat et al., 2005; Schurch et al., 2005), suggesting an 
inhibitory effect on the motor nerves supplying the detrusor muscle. 
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Chapter 4 - Aim and Objectives of thesis 
The use of intra-detrusor BoNT/A has been revolutionary in the treatment of 
patients who are refractory to anti-cholinergic therapy. It is repeatable and the 
treatment appears to be safe and durable in the short to medium term. 
However, several key areas remain unexplained, including the pathophysiology 
of DO and the mechanism of action of BoNT/A, especially in reducing urgency, 
frequency and nocturia.  
 
Both muscarinic receptors and NPY are involved in afferent neurotransmission 
in the bladder. Little is known regarding the expression of superficial muscarinic 
receptors in those with DO as compared to control subjects. We aimed to 
examine a possible role of urothelial and suburothelial muscarinic receptors in 
human NDO/IDO and whether the action of BoNT/A is partly exerted through an 
effect on those receptors.  
 
NPY is a known co-transmitter in neurones containing ACh and is thought to 
inhibit the contractile response of the detrusor. NPY has been shown to change 
with disease states. We aimed to examine the possible role of NPY in human 
NDO/IDO and whether the action of BoNT/A affects NPY density.  
 
BoNT/A has been speculated to act on afferents in the superficial bladder layer 
via its action on SNAP-25. We aimed to examine if SNAP-25 is expressed in 
human urothelium or suburothelium.  
 
99 
 
The aim of this thesis was to look at differences in neurotransmitter and 
neurotransmitter receptor expression in patients with DO before and after 
treatment. The project required the collection of biopsies, acquisition of skills 
necessary to perform immunohistochemistry and development of new protocols 
to successfully stain for the different receptors and peptides. The analysis of the 
slides required skills in computer quantification, database construction and 
statistical testing.  
 
Hypotheses  
1. We hypothesised that there was involvement of the afferent cholinergic 
muscarinic system in the development of detrusor overactivity. We 
proposed to test this hypothesis by comparing muscarinic receptors and 
neuropeptide Y density within the urothelium and suburothelium in 
patients with DO, as compared to control subjects. 
 
2. BoNT/A has a highly specific action on SNAP-25. We hypothesised that 
SNAP-25 was present in the superficial layers of human bladder and this 
was unaltered with disease. We proposed to test if there were differences 
in SNAP-25 immunoreactivity between controls, patients with DO and in 
those treated with BoNT/A.  
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3. Our final hypothesis was based around the mechanism of action of 
botulinum toxin. There is debate as to how the toxin acts to produce 
amelioration of symptoms. We hypothesised that its marked effect on 
sensory symptoms was based on it action at the afferent level, by 
modulating receptor and neurotransmitter expression. We aimed to test 
this by using immunohistochemistry to compare the density of muscarinic 
receptors and the neurotransmitter NPY before and after application of 
BoNT/A. 
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II – Methods 
Chapter 5 - Clinical Methods 
Ethical and Regulatory Approval 
The immunohistochemistry component of this study was part of a larger, 
ethically approved, prospective, single centre phase II open labelled study 
looking into the clinical effects of BoNT/A in patients with detrusor overactivity 
(Popat et al., 2005). All of the investigations performed as part of this thesis 
followed the approval of the study by the local ethics committee (Joint Ethics 
Committee of UCLH / NHNN Trust / Institute of Neurology and Ealing Hospital). 
The permission of this committee is detailed in Appendix A. Clinical Trial 
Authorisation (CTA) for the use of Botox® was sought from the Medicines and 
Healthcare products Regulatory Agency (MHRA) and its predecessor Medicines 
Control Agency (Exceptions from License); the document is detailed in 
Appendix B. University College London Hospitals Trust Research and 
Development Approval was also received and is listed in Appendix C. The study 
was approved prior to the 2004 EU clinical trial legislation and was updated to 
meet the requirements subsequently. 
 
Informed Consent 
Patients were recruited to this study from referrals to the Department of Uro-
neurology at the National Hospital for Neurology and Neurosurgery and the 
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Department of Urology, Ealing Hospital. All BoNT/A treated subjects in the study 
had a history of urgency, frequency and / or urgency incontinence for more than 
one year and were refractory to oral antimuscarinic treatment (at least two 
different formulations), due to either lack of efficacy or intolerable adverse 
effects. Subjects were provided with a patient information leaflet (PIL) (Appendix 
D) and invited to participate by signing a trial specific consent form (Appendix 
E).  
 
Control tissue was obtained from asymptomatic subjects (screened for the 
absence of OAB symptoms) at Ealing Hospital NHS Trust undergoing flexible 
cystoscopy for haematuria. Subjects were also provided with a control biopsy 
specific PIL (Appendix D) and consent form (Appendix E). This study was 
carried out according to principles set out in the Declaration of Helsinki and EU 
Good Clinical Practice (GCP). All health professionals including the subjects‟ 
General Practitioner were kept fully informed.  
 
DO Patient Group 
Patients with a history of urgency, frequency and/or urgency incontinence (as 
defined by the International Continence Society) for more than a year who could 
not be managed by oral medication with or without use of clean intermittent self-
catheterization (CISC), or who had intolerable adverse events from therapeutic 
doses of anticholinergic therapy were considered for this study. There were a 
 
103 
total of 36 patients (13 men and 23 women) with 17 having IDO and 19 having 
NDO.  
 
They underwent a full history, examination, with urine dipstick collection of 3 day 
voiding diaries and urodynamic investigations before a diagnosis of DO was 
made. There were two subgroups: IDO and NDO patients. The causes of NDO 
were multiple sclerosis (15), spastic paraparesis, spina bifida, transverse melitis, 
and spinal cord injury. Mean age was 45.7 years (range 19-63 years).  
 
Inclusion criteria required patients to be willing to perform CISC, in case this 
was required following treatment and the ability to attend afterwards for study 
tests. Exclusion criteria included; women who were pregnant or breast feeding 
or planning pregnancy, patients on anticoagulant therapy, patients with 
neuromuscular transmission disorders and those taking drugs that might 
interfere with neuromuscular transmission (e.g. aminoglycosides).  
 
Urodynamic methods 
Subjects were assessed with standard subtraction cystometry using a filling rate 
of 30 ml per minute, and those with urodynamic evidence of phasic or terminal 
DO were considered suitable to enter the study. Filling was stopped when the 
patient could no longer delay micturition or upon terminal DO; the volume was 
then recorded as the maximum cystometric capacity (MCC). Maximum detrusor 
pressure during filling (Pdetmax) was also recorded as the maximum pressure 
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during phasic or terminal DO. Patients with reduced bladder compliance 
(increased detrusor pressure at low cystometric capacity) in the absence of 
obvious DO were excluded from the study. 
 
Intra-detrusor Injection of Botox® 
Prior to treatment, urine was checked with dipstick for signs of infection and if 
present, a urine specimen was sent for culture, the patient was treated with 
empirical antibiotics and the procedure was postponed.  
 
The skin was prepared with antiseptic solution and 1% lignocaine gel was 
applied to the urethra for lubrication and local anaesthesia. A flexible 
cystoscope (CYF-5, Olympus Keymed, UK) was inserted into the bladder under 
direct vision and the bladder wall examined. Only if the bladder wall was 
considered healthy did the clinician proceed further. All procedures were carried 
out under the supervision of a consultant urologist, Mr Prokar Dasgupta. If there 
was discomfort with the procedure, 20ml of lignocaine gel was injected per 
urethra into the bladder, and the procedure recommenced after 20 minutes. 
 
The Botox® (Allergan Pharmaceuticals, Ireland) was reconstituted and diluted in 
saline solution prior to injection. Patients were injected by using a disposable 27 
gauge flexible needle enclosed in a sterile reusable sheath (NM-101C-0427 set 
includes 1 x reusable sheath and 6 sterile needles, Olympus Keymed, UK) via a 
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flexible cystoscope with a 2.2 mm working channel (Harper et al., 2003; Sahai et 
al., 2006).The toxin was injected in a grid like pattern avoiding the trigone. 
Neurogenic patients were treated with 300 units and idiopathic patients received 
200 units of Botox® injected at 30 and 20 sites respectively. Prophylactic oral 
trimethoprim antibiotic were administered prior to injection with two further 
doses given for the patient to take at home.  
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Chapter 6 - Laboratory methods 
Tissue Retrieval  
Baseline and follow-up biopsies were taken by flexible cystoscope using the 
Olympus 21SX biopsy forceps (Olympus, Tokyo, Japan) from a consistent area 
2cm above and lateral to the ureteric orifices, which collected approximately 
1mm3 of tissue per biopsy. Follow-up biopsies were obtained during check 
flexible cystoscopy at 4 and 16 weeks after each treatment session. Identical 
methodology was used for control subjects. 
 
Three or four biopsies were taken from each subject prior to injection of 
BoNT/A. One specimen was immediately fixed in Zamboni‟s solution (buffered 
picric acid-formaldehyde (Stefanini et al., 1967), while the other two were snap 
frozen in liquid nitrogen. After two hours, the biopsy in Zamboni‟s solution was 
transferred to sucrose based preservative solution (15% sucrose and 0.01% 
sodium azide as cytoprotectant and preservative) and preserved in 4oC. These 
biopsies were used for IHC purposes and for histological examination 
(Apostolidis et al., 2008). The 4th biopsy was fixed in 3% glutaraldehyde or 3% 
glutaraldehyde + 0.1% PFA solutions and was then used for electron 
microscopy examination as part of a different project.  
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Slide mounting 
All samples obtained for IHC purposes were embedded in optimum cutting 
temperature medium (Tissue-Tek®, Sakura USA) and kept frozen at -60oC, until 
cut with a histology cryostat microtome to 10-12 µm sections and collected on 3-
aminopropyltriethoxy-silane (APES) coated Superfrost® slides (VWR, USA). 
Three serially cut sections from each biopsy were placed on each slide to 
capture as much of the same level of the biopsy in each receptor staining. 
Investigators were blinded to the identity of the samples (IDO, NDO, Control, 
Pre or Post BoNT/A) by assigning a unique code at tissue collection. The study 
was unblinded following analysis of all slides at the end of the study. 
 
Bladder Immunohistochemistry 
This protocol was devised at the Institute of Neurology, Queen Square based on 
modifying available protocols using antibody staining with diamino-benzidine 
(DAB) chromogen immuno-localisation from the Hammersmith Hospital.  
 
IHC was extremely labour intensive and required a method development period 
of 18 months and a budget of approximately £7000 in optimising the appropriate 
staining protocol in human tissue and confirming specific immunoreactivity in 
other species. Several experimental trial runs were required to optimise the 
methodology. The problems encountered were antibody specific staining in 
human tissue which required testing of several different commercial antibodies 
(up to 5 different manufacturers) with accurate titration of antibody and using 
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prefixed as opposed to snap frozen tissue. The other difficulty was in the 
reduction of background non-specific staining which required a complex series 
of washes after each stage, reduction of time spent in DAB developer and 
changes in the blocking serum. Specificity of staining was checked with known 
animal tissue staining and western blots using the same antibody. The final 
slides were checked with Dr Alex Freeman, Consultant Pathologist at University 
College Hospital and presented at departmental meetings. 
 
Each experiment required 3 days of preparation with cutting, preparing tissue, 
solutions and slides prior to IHC process which required 2 days. Analysis of 
results took a further week with photographing and quantifying the stained 
tissue. The method development, experimental and analysis phase took a total 
of 3 years to complete.  
 
Figure 12: The indirect method of immunohistochemical staining uses one antibody 
against the antigen being probed for, and a second, labelled antibody against the first. 
(Diagram created by Viki Male in Wikipedia, 14th September 2005) 
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An indirect method of immunohistochemical detection of antigens in tissue was 
used throughout (Figure 12).  
 
This method is more sensitive due to signal amplification through several 
secondary antibody reactions with different antigenic sites on the primary 
antibody. The secondary antibodies were all biotinylated, exploiting the very 
strong affinity avidin has for biotin. Once the avidin-biotin complexes had 
formed, the cut sections were then reacted with 3,3'-Diaminobenzidine (DAB) to 
produce a brown stain wherever primary and secondary antibodies were 
attached. This reaction was further enhanced using nickel, producing a deep 
blue/black stain. 
 
Antibody specificity 
Negative controls with no antibody applied were included in each run. Mouse 
cerebellum and heart specimens were also immunostained for M1, M2 and M3 
receptors as positive controls. Since cognates for pre-absorption tests were 
commercially unavailable and antibody sequences were protected, we 
performed Western blots on fresh tissue homogenates from mouse cerebellum 
and heart using additional immunoprecipitation. Immunoblots revealed 
appropriate major and minor bands for muscarinic receptor antigen. 
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IHC Protocol 
This protocol was used successfully for staining of M1, M2, M3 receptors, SNAP-
25 and Neuropeptide Y. All similar groups of slides were stained together; in 
batches of between 50 and 80 slides. The critical differences in technique for 
the different antigens stained were the primary antibody used and time required 
for final developing.  
 
M2 receptor staining was only successful with snap frozen tissue, and this was 
fixed in 4% Paraformaldehyde solution for 30 minutes, followed by 3 washings 
in Phosphate Buffered Saline (PBS, Oxoid®, Dulbecco `A‟ Tablets U.K.) for 5 
minutes. Prefixed tissue (Zamboni‟s fixed specimens) was used in M1, M3, NPY 
and SNAP-25 staining and did not require the initial paraformaldehyde step. 
Sections were then transferred to 0.3% hydrogen peroxide in Industrial 
Methylated Spirit (IMS, 90% Ethanol and 10% Methanol) for 30 minutes to 
inhibit endogenous peroxidases. Following three further washes with PBS as 
described above, blocking serum was applied for 30 minutes. This was followed 
by another series of PBS washes and the application of the primary antibody 
which was incubated overnight at room temperature.  
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Table 4 : Blocking sera, primary and secondary antibodies used in IHC protocol.  
Primary 
Antibody 
Manufacturer 
/ Antibody 
Blocking 
Serum 
Immunogen Secondary 
antibody 
Rabbit 
polyclonal to 
muscarinic 
Acetylcholine 
Receptor 1  
1:1000 
concentration 
Abcam 
ab3480 
 
1/30 Normal 
Goat Serum 
with 1% BSA 
Fusion protein 
containing 
amino acids 
269-320 from 
human m1 
AChR 
Biotinylated 
Anti-Rabbit 
5 µl/ml 
Rabbit 
polyclonal to 
muscarinic 
Acetylcholine 
Receptor 2  
1:500 
concentration 
Affinity 
Bioreagents 
PA1-23537 
 
1/30 Normal 
Goat Serum 
with 1% BSA 
3rd 
cytoplasmic 
domain of 
human 
Muscarinic 
Acetylcholine 
Receptor M2 
Biotinylated 
Anti-Rabbit 
5 µl/ml 
Rabbit 
polyclonal to 
Muscarinic 
Acetylcholine 
Receptor 3 
1:500 
Concentration  
Abcam 
ab13063 
 
1/30 Normal 
Goat Serum 
with 1% BSA 
2nd 
cytoplasmic 
loop of human 
synthetic 
peptide 
 
Biotinylated 
Anti-Rabbit 
5 µl/ml 
Mouse 
monoclonal to 
SNAP-25 
1:2000 
concentration 
Abcam 
ab24737 
 
1/30 Normal 
Horse Serum 
with 1% BSA 
Full length 
protein 
Biotinylated 
Anti-Mouse 
10 µl/ml 
 
Rabbit 
polyclonal to 
Neuropeptide Y 
1:5000 
concentration 
Abcam 
ab10980 
 
1/30 Normal 
Goat Serum 
with 1% BSA 
Full length 
Neuropeptide 
Y 
Biotinylated 
Anti-Rabbit 
5 µl/ml 
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On the following day after washing with PBS, slides were incubated in 
corresponding secondary antibodies (Vector Laboratories, USA) and made up in 
blocking serum for 45 minutes. This was followed by amplification and 
development of the signal using the avidin-biotin complex (ABC) method 
together with DAB (Shu et al., 1988). The slides were then left in ABC mixture 
(5µl/ml solution A, 5µl / ml solution B in 1% BSA and PBS, VECTASTAIN® Elite 
ABC reagent, Vectorlabs, USA) for 30 minutes, followed by further washes with 
PBS (as above). A proportion of the avidin is also bound to biotinylated 
peroxidase and to biotinylated secondary antibody; this is crucial to the final 
step of development where the peroxidase is developed by DAB-nickel.  
 
Figure 13: Summary of bladder immunohistochemistry protocol 
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One trough (sufficient for 25 slides) of developing solution was produced by 
adding 40ml of 1 M Sodium Acetate (acidified with glacial acetic acid to pH 6.0) 
solution diluted in 360 ml distilled water. To this solution, 10g of Nickel 
ammonium sulphate powder was added. Further to this, 400mg of D-glucose 
was added with 80mg of Ammonium Chloride. At the final stage, 100 mg DAB 
was added together with 4mg of glucose oxidase to catalyse the reaction. The 
DAB-nickel solution in the presence of peroxidase from the ABC converts to a 
blue/black stain which delineates the area where the primary antibody has 
bound. The amount of time spent in the developing solution was highly variable 
depending on concentration and type of antibody used. Development was 
stopped when an adequate signal to noise ratio was achieved. This was 
decided by comparing the amount of cellular or nerve fibre IR to background IR.  
 
Table 5: Time spent in DAB-nickel developer by primary antibody 
Antibody Time in DAB-nickel developer.  
M1 5 minutes 
M2 5 minutes 
M3 8 minutes 
SNAP-25 4 minutes 
NPY 5 minutes 
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Following development, slides were washed in distilled water and placed in 
increasing concentrations of alcohol (50%, 70%, 90% and 100%) and finally 
xylene to achieve dehydration. The slides were incubated in a counter-stain of 
neutral red (0.1%, 0.4g in 400ml with 2 drops of glacial acetic acid) for 20 
seconds and washed with distilled water (x2 for 5 minutes) to label nuclei and 
allowing identification of the urothelium and sub-urothelium. Slides were then air 
dried and cover-slipped with Depex® (Gurr, England) slide mounting media, 
prior to quantification.  
 
Positive and negative controls  
Specificity of the immunostaining was confirmed by the use of both negative and 
positive controls. In each run, two random sections were selected where instead 
of primary Ab, only the blocking serum was added, in order to serve as negative 
controls. For external positive controls mouse cerebellum and heart tissue were 
used, the former are abundant in M1 and M3 receptors and the latter in M2 
receptors. In addition, human detrusor muscle containing biopsies from 
cystectomy specimens were used as internal positive controls.  
 
Image capture 
Slides were analysed on a light microscope (Axioskop 40, Zeiss Germany) with 
images captured by a digital imaging system (Cell D, Olympus UK) based on 
calibrated 5 megapixel images stored at 2576 x 1932 pixels. Between 3 and 20 
digital images taken at x20 high power magnification field were taken per 
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subject slide. The coding on the slides allowed complete blinding for the 
microscope operator as to the diagnosis of the subject and the time-point at 
which the biopsy was taken.  
 
Computer Quantification 
All slides were analysed by using Cell D image quantification software 
(Olympus, Tokyo, Japan), which allowed threshold to be set around the DAB-
nickel blue-black chromogen. A filter was then set, capturing the blue-black 
elements in the HPF. Holes or tears in the tissue were excluded either by 
cropping the image or the computer detecting areas corresponding to artefacts 
and removing this from the total image area. Areas detected as artefact or 
analysable tissues were checked by the author. The software allowed analysis 
of every image taken and determined the stained percentage per HPF. This 
same filter was then applied to all the sections in that staining run. Each image 
was checked for “real” staining and any artefacts were excluded. The 
quantification results were exported to a spread sheet (Excel 2007, Microsoft 
Seattle, WA USA) where all the results from each individual subject were then 
combined. A mean percentage and standard error of the mean (SEM) were then 
calculated. This was transferred to a database (Access 2007, Microsoft Seattle, 
WA USA) where the results could be unblinded and analysed for differences 
between groups.  
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Quality control 
Semi quantification  
During analysis of the M1 receptor slides, a blinded visual grading system of 
scoring (0-3) was adopted according to the numbers of suburothelial nerve 
fibres displaying M1 receptor staining. This went up in increments of 0.5, each 
increment being equivalent to up to 5 additional immunoreactive fibres per 
section. These results were then compared to results obtained by computer 
quantification and showed good correlation and validity. This method had been 
successfully used in earlier studies, as a semi-qualitative measure (Apostolidis 
et al., 2005a; Apostolidis et al., 2005b). 
 
Blinded repeatability analysis 
To ensure computer quantification was accurate we devised a repeatability test 
using three different subjects‟ bladder biopsies. Four slides containing serial 
sections from each subject were used to determine the mean staining density. 
These slides were blinded from the investigator and randomised. These 12 
slides were stained for SNAP-25 and computer quantified. Once the analysis of 
staining density was complete, the slides were unblinded and each individual 
slide correlated to the population mean (combination of three slides) for the 
subject. The calculated correlation co-efficient was 0.756, indicating validity of 
the computer quantification process.   
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Statistical Methodology 
For clinical urodynamic results we used one way repeated measure ANOVA 
with Bonferroni‟s multiple comparison test correction. 
 
We applied the same statistical plan consistently to our IHC M1, M2, M3, NPY, 
SNAP-25 and urothelial M1 / M3 analyses. Two tests were used for the bulk of all 
analyses. All datasets were skewed and did not normalise using logarithmic 
transformations, consequently nonparametric tests were used. 
 
Comparing control and baseline DO patients, we used a non-parametric test 
(Mann Whitney) to statistically show if groups were different.  
 
To evaluate for a treatment effect of BoNT/A, we used a non parametric 
analysis of variance test ("Kruskal-Wallis test"). This prevents bias from repeat 
testing. Only when this was significant did we perform a post-test (Dunn‟s 
multiple comparison test) for comparison between the three groups (baseline, 4 
weeks, 16 weeks).  
 
Statistical advice and planning for this project was in conjunction with Dr Aviva 
Petrie, Head of Biostatistics Unit and Senior Lecturer at UCL. Specialist 
statistical analytical software was used (GraphPad Prism version 5.01 for 
Windows, GraphPad Software, San Diego California USA, www.graphpad.com). 
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III - RESULTS  
 
From the 36 DO patients involved in the study, only a proportion of biopsies 
were available for staining and analysis for each antigen (Table 6). There were 
a total of 9 subjects control available for control. Complete biopsies sets were 
not available for analysis for the following reasons; patient discomfort, infection, 
loss of tissue on slide, inadequate fixation, tearing of biopsy, folding of specimen 
on slide and small size inadequate for analysis. To account for incomplete sets, 
unpaired analyses were performed. The M3 group in particular had few paired 
biopsies. No duplication of biopsies occurred within each studied antigen group.  
  
Table 6: Total number of patients in each part of the study and the number of biopsies 
available for analysis at each time point.  
Studied 
antigen 
Control 
Biopsies 
Total 
number of 
DO 
Patients 
Baseline 
DO 
Biopsies 
Post – 
BoNT/A 4 
week DO  
Biopsies 
Post – 
BoNT/A 16 
week DO  
Biopsies 
M1 6 28 24 18 16 
M2 7 36 19 15 17 
M3 5 34 15 11 9 
SNAP-25 8 32 27 21 17 
NPY 9 31 21 16 14 
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Chapter 7 - Clinical Urodynamic results 
Of the 36 patients, 35 patients had evaluable traces at all stages of the study. 
One patient had infection prior to follow-up cystometry and did not have a full 
set of results. There were 13 men and 23 women, with 17 having IDO and 19 
having NDO.  
 
Table 7 summaries the cystometry, bladder diary and QOL results from the 
patients at baseline, 4 weeks and 16 weeks after intradetrusor BoNT/A. All 
patients in this cohort achieved significant improvements.  
 
Highly significant mean improvements were noted in urodynamic parameters 
and symptoms assessed by bladder diaries in both the NDO and IDO patients 
and at both follow-ups. Symptomatically and objectively there were considerable 
improvements in patient symptoms of frequency, urgency and urgency 
incontinence both at 4 and 16 weeks after BoNT/A injection. Quality of life 
improved greatly in both patient groups. One way repeated measure ANOVA 
with Bonferroni‟s Multiple Comparison Test Correction was used to determine 
significance. Efficacy was maintained when patients on antimuscarinic 
medication were  analysed as a separate group.  
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Table 7: Summary of urodynamic and clinical results from the patients who provided 
bladder tissue for the purposes of this study.  
  Pre 4/52 16/52 P Value 
Pre vs.  
4/52 
P Value 
Pre vs.  
16/52 
MCC (ml) IDO   225.6 ± 
27.8 
363.9 ± 
41.8 
304.9 ± 
36.5 
0.0008 <0.05 
 NDO 216.2 ± 
33.3 
533.8 ± 
39.0 
425.4 ± 
37.1 
< 0.0001 < 0.0001 
Pdet 
(cmH20) 
IDO   66.5 ± 11.5 36.1 ± 
7.7 
49.6 ± 7.8 0.0001 0.0001 
 NDO 65.8 ± 8.0 28.8 ± 
4.4 
26.5 ± 3.7 < 0.0001 < 0.0001 
Frequency  IDO   13.4 ± 1.2 7.1 ± 1.2 7.5 ± 0.8 < 0.0001 < 0.0001 
 NDO 12.3 ± 1.1 5.3 ± 1.1 6.2 ± 0.4 < 0.0001 < 0.0001 
Leak  IDO   5.4± 1.0 0.3 ± 0.1 0.6 ± 0.3 < 0.0001 < 0.0001 
 NDO 4.0 ± 0.7 0.3 ± 0.7 0.9 ± 0.2 < 0.0001 < 0.0001 
Urgency IDO   11.1 ± 1.7 4.3 ± 0.9 5.1 ± 1.2 0.0002 <0.01 
 NDO 7.6 ± 1.0 1.3 ± 0.3 1.4 ± 0.3 < 0.0001 < 0.0001 
QOL IDO   116.0 ± 7.8 91.5 ± 
7.8 
84.8 ± 7.2 <0.05 <0.0026 
 NDO 121.4 ± 6.4 77.9 ± 
5.1 
84.1 ± 5.1 < 0.0001 < 0.0001 
 
MCC: maximum cystometric capacity, Pdet: maximum detrusor pressure during 
filling, Urgency: number of micturition episodes per 24 hours associated with 
urgency, Leak: number of urgency incontinence episodes per 24 hours, Frequency: 
total number of micturition episodes per 24 hours, QoL: quality of life scores 
assessed with the ICS-BPH questionnaire.  
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Chapter 8 - Muscarinic Receptor 1 
A total of 28 patients' and 6 control subjects‟ biopsies were stained with M1 
receptor antibody. There were six controls (mean age 58.3 years, range 30.0 – 
75.4 years), 40 NDO biopsies (mean age 47.3 years, range 29.2 – 66.3 years) 
and 18 IDO biopsies (mean age 45.9 years, range 27.3 – 60.7 years). Over 581 
HPF images were analysed. Mean percentage of M1 staining per x20 High 
Power Field (HPF) values were taken from each slide. Staining patterns showed 
the presence of M1 receptors in the urothelium and sub-urothelium (Figure 14 & 
Figure 15) with a higher power image (x40) in Figure 16.  
 
A positive control slide showed positive cellular M1 immunoreactivity in mouse 
cerebellum (Figure 17).  
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Figure 14: M1 immunostained slide showing apical urothelial immunostaining (A), 
staining of fibre like structures (B) and cellular staining in the form of either cytoplasmic 
immunostaining or that of bipolar cellular processes (C). 
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Figure 15: M1 Immunostaining in the suburothelial layer. The urothelium which also 
shows staining (A) is present at the edge. Multiple fibre like structures (B) and bipolar 
cellular processes (C) are also seen.  
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Figure 16: M1 Suburothelium; Higher power view (x40) of fine fibre like projections in the 
suburothelium. 
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Figure 17: M1 receptor cellular immunoreactivity present on Purkinje cells (arrow) and in 
the molecular layer of the mouse cerebellum (Positive Control) 
 
There was observed presence of M1 immunoreactivity in the apical layer of the 
urothelium (Figure 14). No M1 labelled nerves were noted to be present within 
the urothelium. In the sub-urothelial layer there was abundant immunostaining 
of fibre like structures (Figure 15). There was also evidence of immunostaining 
on cells with bipolar processes. Negative controls stowed no staining (Figure 
18). 
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Figure 18: Negative control slide in M1 receptor staining protocol 
 
The results and statistical analysis on the suburothelial M1 receptors are shown 
below. There was a significant mean reduction (Figure 19) in M1 suburothelial IR 
(immunoreactivity) from 1.71% in the control group to 0.63% in the IDO subjects 
and 0.88% in the NDO subjects (p=0.014 and 0.036 respectively).  
 
Following BoNT/A, there was a significant increase (Figure 20) in M1 sub-
urothelial staining from 0.794% to 1.61% (4 weeks) and 1.73% (16 weeks) 
(p=0.036 and 0.019 respectively), with a return to control value levels.  
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Figure 19: Statistically significant difference in suburothelial M1 immunostaining between 
Controls and Baseline IDO and NDO subjects 
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Figure 20: Normalisation of M1 suburothelial immunostaining following application of 
BoNT/A at 4 and 16 weeks 
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In the urothelium, there were fewer biopsies for analysis (controls=6, baseline 
DO=14, 4 weeks=13, 16 weeks=9), but there was a similar marked decrease 
(Figure 21) in M1 IR in patients with DO at baseline, when compared to controls 
(3.2% vs. 19.5%). M1 receptor IR statistically increased 16 weeks after BoNT/A 
injection to 8.2% (significance not noted at 4 weeks).  
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Figure 21: Urothelial M1 receptor staining. Statistical significant difference between 
Control (Mean 19.5%) and Baseline (3.2%) DO patients. Following BoNT/A, there is a 
significant increase in urothelial staining at 16 weeks (8.2%) 
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Chapter 9 - Muscarinic Receptor 2  
41 subject slides were stained with antibody for the Muscarinic M2 receptor 
(controls =7, IDO =10, NDO = 24). 19 biopsies were obtained from baseline DO 
patients (Mean 43.0 years, Range 19.6 - 61.6 years), 15 biopsies (Mean 44.0 
years, Range 19.6 - 61.6 years) from patients who had 4 week follow-up after 
BoNT/A injection, and 17 biopsies from patients (Mean 46.1 years, Range 19.6 - 
60.5 years) who had 16 week follow-up biopsies.  
 
 
 
Figure 22: M2 Receptor staining showing fibre like neuronal staining (A) and cellular 
staining from cytoplasmic immunoreactivity or from cellular processes (B) in the 
suburothelial layer (x 20 HPF). Clusters of suburothelial M2 staining were noted.  
 
130 
M2 receptor staining showed no background staining (Figure 22 and Figure 23). 
 
 
 
Figure 23: M2 Staining predominantly in sub-urothelial layer. This section has muscle 
present also. Clusters of M2 fibre like staining (A) present in a layer in the sub-
urothelium. Staining of fibres within muscle was also demonstrated (B) (Image Taken at 
x10 HPF). 
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Figure 24: High power view (x20) of cluster of M2 fibres in the suburothelium. 
 
 
 
Immunostaining was confined mainly to the sub-urothelial layer with little IR in 
the urothelium (Figure 23 and Figure 24). IR distribution highlighted fibre like 
structures as well as cellular staining in discrete clusters in the suburothelium 
(Figure 24).  A few specimens had muscle tissue within the biopsy, and these 
showed fibre neuronal staining (Figure 23). Negative controls showed no DAB 
chromogen staining, whereas mouse heart tissue showed positive IR (Figure 
25).  
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Figure 25: Positive control mouse heart tissue showing M2 immunoreactivity. These 
receptors have been shown to be present on mammalian heart tissue (Sharma et al., 
1997) 
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A total of 494 HPFs with urothelium and suburothelium were taken from the 59 
slides and analysed based on DAB-nickel chromogen. There was no statistical 
difference found in M2 immunoreactivity density between controls and patients 
with IDO or NDO (Figure 26), but there was a decreasing trend. 
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Figure 26: No difference between control and baseline DO M2 immunoreactivity 
 
Following BoNT/A administration, there was a significant increase in mean M2 
receptor suburothelial IR from baseline (0.74%) to 4 weeks (1.62%) and 16 
weeks (1.35%) (p=0.013 and 0.018 respectively) (Figure 27). 
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Figure 27: Significant increase in M2 receptor immunoreactivity at 4 and 16 weeks after 
BoNT/A. 
 
A subgroup analysis showed there was an increase in the NDO group after 
BoNT/A, but not in the IDO population. This could have been be due to smaller 
number of specimens when performing a subgroup analysis (Figure 28 and 
Figure 29). The timing of change after BoNT/A was different with NDO cohort 
responding earlier than the IDO cohort. 
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Figure 28: NDO cohort showing an increase in M2 receptor IR after 4 weeks following 
BoNT/A (p=0.028). 
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Figure 29: IDO sub-group showing no significant change in M2 IR after BoNT/A  
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Chapter 10 - Muscarinic Receptor 3  
41 patients‟ biopsies (controls=5, IDO =17, NDO= 19) were stained for sub-
urothelial and urothelial M3 receptors. Of 47 slides, 9 slides were excluded due 
to poor quality of sections which were unsuitable for analysis. There were five 
controls (mean 48.9, range 32.4 – 72.0 years), 13 baseline DO biopsies (mean 
age 46.1, range 29.2 – 61.6 years), eleven 4-week follow-up biopsies (mean 
age 43.8, range 21.1 – 60.7 years) and nine 16-week follow-up biopsies (mean 
age 46.5, range 27.3 – 61.6 years).  
 
Figure 30: M3 receptor immunostaining in suburothelium showing neuronal staining (A) 
and cell body staining (B). Neuronal and cell body staining is also noted in the detrusor 
muscle layer (C) x 10 HPF. The urothelium here is not completely intact.  
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M3 receptor immunoreactivity was present in the apical layer of the urothelium, 
suburothelium, detrusor muscle layer and blood vessel endothelial cells (Figure 
30 and Figure 31).  
 
 
 
Figure 31: M3 Immunoreactivity in the urothelium and suburothelial layer. Cellular 
staining is seen in the suburothelium (A). The apical urothelium is also immunoreactive 
(B). 
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Figure 32: M3 immunoreactivity present in suburothelial endothelial cell (A) and cellular 
staining within the muscle layer (B) x20 HPF. 
 
Figure 33: M3 receptor staining in the apical layer of the urothelium (A) (x20 HPF). 
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Positive controls from mouse species were used to ensure antibody specificity 
(Figure 34 and Figure 35). 
 
 
Figure 34: Mouse cerebellum showing positive M3 staining of the Purkinje cells (x10 
image) 
 
 
Figure 35: Mouse heart muscle demonstrating M3 immunoreactivity (x40 image) 
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A total of 332 HPF images of urothelium and suburothelium were taken from the 
47 slides and analysed using computer image quantification based on DAB-
nickel chromogen. There were differences in suburothelial M3 receptor IR 
between control subjects (5.97%) and baseline DO specimens (1.62%) 
(p=0.015) (Figure 37). Subgroup analysis showed these differences were 
present in the baseline NDO and IDO populations (Figure 36, both groups, 
p=0.03), when compared to controls.  
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Figure 36: Comparison of M3 receptor suburothelial immunoreactivity between groups. 
Differences were found between controls and IDO and NDO subjects (both p=0.03). 
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Figure 37: M3 receptor suburothelial immunoreactivity density per HPF for the total DO 
population. A difference was seen between controls and baseline value (p=0.015).No 
change was noted after BoNT/A treatment. 
 
Suburothelial M3 receptor IR remained unchanged at both follow-up time points 
following injections of BoNT/A (Figure 37).   
 
Urothelial M3 staining 
There was significant M3 receptor IR present within the urothelium (Figure 31 
and Figure 33), which was analysed separately from the suburothelium. 19 out 
of 35 patients‟ slides had urothelium present suitable for analysis (IDO=8, 
NDO=11). This showed a significant increase in immunoreactivity following 
BoNT/A at 16 weeks (p=0.03, Figure 38). There was insufficient control M3 
stained urothelial tissue to make a valid comparison.  
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Figure 38: Increase in M3 urothelial immunoreactivity density following BoNT/A 
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Chapter 11 - SNAP-25 
40 patients (controls=8, IDO=12, NDO=20) with 73 biopsies were stained for 
SNAP-25 protein. There were seven controls (mean 60.8, range 32.4 – 77.9 
years), 27 baseline biopsies (mean 48.1, range 27.3 – 66.8 years), 21 4-week 
follow-up biopsies (mean 46.7, range 27.3 – 66.3 years) and 17 16-week (mean 
44.6, range 27.3 – 55.3 years) follow-up subject biopsies. Neuronal like 
structures immunoreactive for SNAP-25 were clearly visible in the suburothelial 
layer, but no IR was present within the urothelium (Figure 40).  
 
 
Figure 39: SNAP-25 Human Bladder Negative Control with no primary antibody 
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Figure 40: Urothelial staining was not present (A). SNAP-25 staining throughout sub-
urothelium (B) on fibre-like structures (x10 HPF image). 
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Figure 41: Neuronal SNAP-25 staining in the suburothelium (A). No staining was present 
within the urothelium (B) (x20 image). 
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Figure 42: Low power (x2.5) photo of biopsy. Layers are labelled. 
 
 
Figure 43: Same section as above but at x20 magnification. Neuronal SNAP-25 
immunoreactivity present in suburothelium (A), with minimal immunoreactivity observed 
in muscle (B) 
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Figure 44: Section demonstrating SNAP-25 suburothelial(A)  and muscle (B) 
immunostaining. 
A total of 660 (x20 magnification) HPF images were quantified for SNAP-25 
immunoreactivity. There was no overall difference in SNAP-25 immunoreactivity 
density between control, baseline and follow-up groups (Figure 45). This did not 
change when subgroup analysis was performed (Figure 46).  
 
  
 
148 
SNAP-25
C
on
tr
ol
B
as
el
in
e
4 
w
ee
ks
16
 w
ee
ks
0.0
0.5
1.0
1.5
n=8 n=27 n=21 n=17
Stage
%
S
N
A
P
-2
5
 p
e
r 
H
P
F
 
Figure 45: No difference was observed in SNAP-25 immunoreactivity between any of the 
groups. 
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Figure 46: No significant change in SNAP-25 IR within IDO / NDO subgroups following 
BoNT/A 
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There were 13 biopsies which included muscle below the suburothelium. Paired 
sampling of suburothelium and muscle in those specimens showed less SNAP-
25 immunoreactivity in the muscle (0.583%) compared to the suburothelial layer 
(0.831%) (One way ANOVA, P<0.0001) (Figure 43, Figure 44, Figure 47).  
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Figure 47: Comparison of Suburothelial and Muscle Immunoreactivity for SNAP-25 
protein. Muscle IR was significantly less (One way ANOVA, p<0.0001) 
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Chapter 12 - Neuropeptide Y 
40 patients (controls=9, DO=31) were included with 70 biopsies stained with 
antibody for NPY. 10 biopsies were rejected for poor quality of sections (folded, 
minimal tissue and dropped off sections). There were nine controls (mean 62.1, 
range 32.4 – 77.9 years), 21 baseline (mean 47.9, range 27.3 – 66.3 years), 16 
4-week follow-up (mean 49.1, range 29.2 – 66.3 years) and 14 16-week follow-
up (mean 42.6, range 27.3 – 55.3 years) subject biopsies.  
 
NPY immunoreactivity was present in the apical layer of the urothelium. Fibre 
like structure IR was present within the suburothelium, with no fibre like staining 
present in the muscle layer (limited sections of tissue with muscle present).  
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Figure 48: NPY immunoreactivity in apical layer of the urothelium (A). Very little IR was 
observed in the basal or middle layers (B). Fibre like staining was present in the 
suburothelium (C) (x 40 magnifications). 
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Figure 49: Suburothelial NPY immunostaining was observed in fibre-like structures (A). 
No specific fibre like NPY immunostaining was seen in the muscle layer (x10) 
 
Over 600 images were quantified for NPY immunoreactivity. An increase in NPY 
immunoreactivity was observed between controls (0.29%), compared to patients 
with DO (1.00%) (p=0.02, Figure 51). Subgroup analysis of controls compared 
to IDO and NDO baseline patients did not show significant difference, due to 
lower numbers (Figure 50). Following administration of BoNT/A there were 
reductions in mean immunoreactivity towards control values, especially at 16 
weeks (0.38%), but this did not achieve statistical significance on the Kruskal-
Wallis test (Figure 51).  
 
 
153 
NPY Baseline
C
on
tr
ol
ID
O
N
D
O
0.0
0.5
1.0
1.5
2.0 n=9 n=8 n=13
%
N
P
Y
 S
ta
in
in
g
 p
e
r 
H
P
F
 
Figure 50: Subgroup analysis of controls compared to IDO and NDO baseline patients. 
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Figure 51: DO baseline biopsies showed an increase in NPY immunoreactivity density 
when compared to control subjects (p=0.02). There was a trend towards normalisation 
following BoNT/A, but this did not achieve significance. 
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Table 8: Summary of immunohistochemistry results.  
 
Layer and 
Receptor 
Control 
Subjects 
Baseline DO 4 weeks post 
BoNT/A 
16 weeks 
post BoNT/A 
Suburothelial 
M1 
1.711% 
(±0.4409) 
0.7935%* 
(±0.1025) 
1.612%** 
(±0.3354) 
1.734%** 
(±0.3608) 
Suburothelial 
M2 
1.191% 
(±0.3119) 
0.7422% 
(±0.1909) 
1.628%** 
(±0.4251) 
1.353%** 
(±0.2546) 
Suburothelial 
M3 
5.973% 
(±1.935) 
1.625%* 
(±0.4222) 
1.801% 
(±0.6151) 
1.948% 
(±0.7709) 
Urothelial M1 19.52% 
(±5.490) 
3.161%*  
(±0.7602) 
4.576% 
(±1.278) 
8.211%** 
(±1.811) 
Urothelial M3 No Data 0.5623% 
(±0.4017) 
2.0555% 
(±0.9837) 
5.864%** 
(±2.875) 
SNAP-25 0.8884% 
(±0.3482) 
0.9445% 
(±0.2321) 
0.9840% 
(±0.2183) 
0.9840% 
(±0.1805 
NPY 0.2984% 
(±0.08732) 
1.002%* 
(±0.2786) 
0.6440% 
(±0.2357 
0.3819% 
(±0.1740) 
Mean percentage staining per HPF (±Standard Error of the Mean) 
*= significant difference between Baseline DO and Control biopsy 
immunoreactivity. 
**= significant difference between Baseline DO and post BoNT/A 
immunoreactivity. 
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Chapter 13 – Immunohistochemistry correlations with 
clinical symptoms. 
 
Inverse correlations were found between suburothelial IR levels of each 
receptor in the whole DO population, and the number of urgency episodes 
before and after treatment (M1 receptor r = -0.34, p = 0.012, M2 receptor r = -
0.34, p = 0.048 and M3 receptor r = -0.39, p = 0.039, Figure 52, a, c and e). 
Inverse correlations were also noted between suburothelial M1 and M3 receptor 
levels, and the number of voids per 24 hours before and after treatment (r = -
0.30, p=0.024 and r = -0.44, p = 0.020, respectively, Figure 52, b and f). 
 
A weak trend was noted for a correlation between M2 receptor levels and 
micturition frequency (r = -0.31, p = 0.094, Figure 52, d). Urothelial M3 receptor 
levels inversely correlated with urgency (r = -0.51, p = 0.049). Urothelial M1 
receptor levels showed only a trend toward correlation with urgency (r  = -0.32, 
p = 0.082). Stronger correlations were noted between urothelial receptor levels 
and micturition frequency (M1 receptor r = -0.41, p = 0.017 and M3 receptor r  = 
-0.64, p = 0.006) (Figure 53). 
 
156 
 
Figure 52: Receptor suburothelial IR by number of urgency and micturition episodes per 
24 hours in whole DO population using Spearman r test, including values at baseline, and 
4 and 16 weeks. Inverse associations were found between quantified urgency and IR for 
M1 (r=-0.34, p=0.012) (a), M2 (r=-0.34, p= 0.048) (c) and M3 (r=-0.39, p=0.039) receptors (e). 
M1 (r=-0.30, p=0.024) (b) and M3 (r=-0.44, p=0.020) (f) receptor levels also correlated 
inversely with 24-hour micturition frequency. Weak trend was noted for M2 receptor 
association with micturition frequency (r=-0.31, p=0.094) (d). Urothelial receptor levels 
were also inversely associated with patient symptoms. 
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Figure 53: Receptor urothelial IR by number of urgency and micturition episodes per 24 
hours in whole DO population using Spearman r test, including values at baseline, and 4 
and 16 weeks. Inverse associations were found between quantified urgency and IR for  
M3 (r= -0.5143 , p = 0.0498) (c). M1 (r = -0.4064, p = 0.0171) (b)  and M3 (r = -0.6384, p = 
0.0058) (d) urothelial receptor levels also correlated inversely with 24-hour micturition 
frequency.  
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Chapter 14 – Subgroup analysis on the effect of 
antimuscarinics.  
 
To assess a possible synergistic effect of antimuscarinics we separated results 
at each time point and analysed for antimuscarinic use versus non-use by 
applying the Mann-Whitney test. 
 
The incidence of patients on antimuscarinics decreased from 52.8% at baseline 
to 27.8% 4 weeks and 30.6% 16 weeks after treatment. Clinical outcomes were 
independent of antimuscarinic use at all time-points (Figure 54). Muscarinic 
receptor IR was no different in antimuscarinic users versus nonusers at all time-
points (Figure 55). However, with very few antimuscarinic users at certain time 
points, we were not adequately able to compare urothelial M3 receptor at all 
time-points or suburothelial M3 and urothelial M1 receptors at 16 weeks. 
 
We observed no statistical differences in clinical parameters or immunoreactivity 
between subjects that took antimuscarinics and those that did not.  
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Figure 54: Clinical outcomes of BoNT/A were independent of antimuscarinic (AM) use at 
all time-points.  
 
160 
 
Figure 55: No statistical differences were seen in immunoreactivity in antimuscarinic 
users versus nonusers at all time-points. Large standard errors are reflective of smaller 
numbers in the AM groups.  
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IV - Discussion 
Chapter 15 
This is the first study, to our knowledge, to assess the effect of BoNT/A on the 3 
muscarinic ACh receptors M1, M2, M3 and NPY in the human bladder in both 
idiopathic and neurogenic DO. It is also the first study to investigate M1 
receptors in human overactive bladder conditions. The pattern of muscarinic 
receptor IR in the suburothelium and in muscle layers was similar to that 
reported by other groups (Mukerji et al., 2006; Jositsch et al., 2008). 
 
There is current controversy regarding the mechanism of action of intra-detrusor 
BoNT/A; whether this acts in the urothelium / suburothelium, the detrusor 
muscle layer, or possibly both. This is in addition to the different proposed 
theories surrounding the pathophysiology of DO and where antimuscarinic 
drugs may be acting. Kuo showed no difference in outcome in a randomised 
study looking at BoNT/A injection either into the suburothelium or in the detrusor 
layer (Kuo, 2007). It is likely that BoNT/A diffuses through to both layers once 
injected (Mehnert et al., 2009). Initially it was thought that BoNT/A would 
produce a paralysis of the detrusor smooth muscle (Schurch et al., 2000), 
similar to its action in skeletal muscle (Dolly, 2003). However others have 
suggested that the urothelium and suburothelial complex has been shown to be 
crucially involved in a sensory mechanism and can release chemical mediators 
that may be involved in the pathogenesis of OAB and DO (Birder and de Groat, 
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2007). BoNT/A with its remarkable clinical efficacy at ameliorating symptoms of 
urgency (Kalsi et al., 2007) and frequency has led others to propose that at least 
part of its action is via modulation of afferent pathways (Apostolidis et al., 2006).  
 
There is complex crosstalk at the urothelial, suburothelial and myofibroblast 
interface with involvement of ATP, ACh, NO and SP neurotransmitters 
modulating peripheral afferent input and contributing to a sensory web 
(Apostolidis et al., 2005b; Apostolidis et al., 2006; Birder and de Groat, 2007; 
Hanna-Mitchell et al., 2007). 
 
Discovery of BoNT/A effects on TRPV1 and P2X3 receptors has prompted 
research into its effects on other putative afferent receptors found in the 
urothelium and suburothelium (Apostolidis et al., 2005b).  
 
Following detrusor BoNT/A injections, urodynamic results showed significant 
improvements in all clinical parameters with decreases in frequency, urgency 
and incontinence episodes. There were also improvements in bladder capacity 
and quality of life. These results are comparable to those observed in other 
studies (Schurch et al., 2005; Sahai et al., 2007). 
 
Suburothelial muscarinic receptor IR was decreased in patients with DO, 
significantly in M1
 
and M3, and to a lesser degree in M2. Following treatment with 
BoNT/A, M1
 
and M2
 
IR were increased to levels close to control values, but M3
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immunoreactivity remained unchanged. Urothelial M1
 
immunoreactivity followed 
the suburothelial pattern of changes. Similar post-BoNT/A increases were noted 
in the urothelial expression of M3
 
receptors. 
 
There was inverse correlation between patients symptoms of urgency and 
frequency and muscarinic receptor density.  
 
NPY IR was increased in DO patients compared to healthy controls. Following 
BoNT/A application, there was a decreasing trend in NPY IR. SNAP-25 IR was 
found abundantly in the suburothelial layer in fibre like structures, with no 
changes following treatment.  
 
Muscarinic receptors  
It has been postulated that urothelial M1 receptors respond to the paracrine / 
autocrine release of acetylcholine (Hanna-Mitchell et al., 2007). M1 receptors in 
the rat urinary detrusor are thought to be autocrine facilitatory presynaptic 
receptors which enhance the release of ACh (Somogyi et al., 1994). The 
activation of the M1 receptors is thought to modulate the neural input for bladder 
contraction during voiding. In Bschleipfer's study, M1 receptors were shown to 
be localised to the basal layer of the urothelium (Bschleipfer et al., 2007), 
contrary to the finding in our study. 
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Acetylcholine (ACh) is a phylogenetically ancient molecule involved in cell-to-
cell signalling in almost all life-forms on earth (Kawashima and Fujii, 2008). 
Cholinergic components, including ACh and choline acetyltransferase have 
been identified in keratinocytes, cancer cells, immune cells, urinary bladder, 
airway epithelial cells, vascular endothelial cells and reproductive organs. It is 
thought to be an important molecule in signal transduction.  
 
There is a basal release of ACh from the bladder, which increases with age and 
decreases with removal of the mucosa (Yoshida et al., 2004; Yoshida et al., 
2006). Choline acetyltransferase, an enzyme required for ACh synthesis, has 
been shown to be present within the urothelium (Yoshida et al., 2008).  
 
Our results show for the first time immunohistochemical evidence for the 
presence of M1 muscarinic receptors in the urothelium and suburothelium of 
human overactive bladders as well as healthy controls. We demonstrated apical 
urothelial staining, whereas previously this was shown only in the basal layer 
(Bschleipfer et al., 2007). Differences in the fixation protocol and in the use of 
commercial antibodies may account for the discrepancies noted in the presence 
and localisation of muscarinic receptor IR in the urothelium, compared with 
previous studies. The differences observed by Bschleipfer et al. may have been 
partly due to their use of patients' tissue with different pathological conditions 
(bladder cancer, carcinoma-in-situ and interstitial cystitis), where there may 
have been pathological urothelial turnover. It has been shown that bladder 
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urothelial cancer cells have altered muscarinic signalling and receptor 
expression (Tully et al., 2009). Their study was also limited to 8 older female 
patients. Our study showed the presence of M1 receptors in apical urothelial 
cells in patients with DO. This finding could be related to the pathophysiology of 
DO, where M1 receptors may appear throughout the urothelium. 
 
Urothelial IR quantification could only be established for M1
 
and M3. In contrast 
to previous publications where the investigators used a different M2
 
receptor 
antibody (Mukerji et al., 2006), we only observed non-evaluable urothelial M2 
immunoreactivity in patients with DO.  
 
Muscarinic M1 IR could be identified in the suburothelium on fibre-like structures 
and on cells with bipolar processes, morphologically resembling nerve fibres 
and interstitial cells/myofibroblasts, although double-staining experiments were 
not performed to confirm this. In the detrusor, IR was seen on fibre-like 
structures and endothelial cells.  
 
Relative decreases were noted in urothelial as well as suburothelial M1 IR in 
biopsies from DO patients prior to treatment, when compared to control 
subjects. The relative decrease was noted in both IDO and NDO groups. 
Whether M1 receptors in the urothelium perform this same facilitatory role as 
noted in the detrusor muscle is unknown. 
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It is well established that prolonged exposure of G protein coupled receptors to 
agonists results in a reduction in receptor mediated responses, through 
regulatory mechanisms that involve phosphorylation, G protein uncoupling, 
internalization and down-regulation (Wess, 1996; Ferguson, 2001; van Koppen 
and Kaiser, 2003). The M1 and M3 receptors have been shown to be 
phosphorylated by protein kinase C (PKC) both in-vitro and in-vivo in an agonist 
independent manner (Uchiyama et al., 1990; Richardson and Hosey, 1992; 
Haga et al., 1996). Phosphorylation of muscarinic receptors by PKC results in 
receptor protein downregulation and a reduction in their mRNA levels, with 
significant loss of cell surface muscarinic receptors (Liles et al., 1986; Rousell et 
al., 1995). This PKC phosphorylation is more prominent in M1
 
and M3 than in M2
 
receptors (Haga et al., 1993), in line with the findings of our study. The decrease in 
M1 and M3 IR in DO observed in our study may result from a compensatory 
mechanism to reduce facilitation, in a system with an increased ACh release 
from the urothelium.  
 
There is evidence that there is plasticity in muscarinic receptor expression and 
this has been shown in spinal cord transected rats, where other receptor 
subtypes (M3) take on a facilitatory role from low affinity M1 receptors (Somogyi 
and de Groat, 1999).  An increase in non-neuronal ACh could be the underlying 
primary pathology of DO, which has been noted to occur with age and detrusor 
stretch (Yoshida et al., 2004; Yoshida et al., 2006).  
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Following successful treatment of DO with BoNT/A, there is a normalisation of 
suburothelial IR for M1 both at 4 and 16 weeks. Urothelial and suburothelial 
increases in M1 IR after BoNT/A may occur due to reduced amounts of ACh 
now able to activate the receptor, resulting in reduced PKC phosphorylation. It is 
known that receptor downregulation is reversed when PKC is inhibited (Liles et 
al., 1986).  
 
Normalisation changes with BoNT/A have been reported in urothelial ATP and 
NO neurotransmitter release (Smith et al., 2008). Similarly suburothelial P2X3 
and TRPV1 receptors have normalised with BoNT/A treatment (Apostolidis et 
al., 2005b). In the case of P2X3 and TRPV1 receptors, levels decreased, but with 
muscarinic receptors there appeared to be an increase following successful 
BoNT/A treatment. This may illustrate the opposing actions of the 
neurotransmitter systems in the suburothelium.   
  
In the urothelium the increase in M1 receptor is only significant at 16 weeks, 
which may indicate a slower pattern of change as compared to the 
suburothelium. In addition, this increase in IR was not as pronounced as the 
normalisation seen in the suburothelium, suggesting that BoNT/A may not have 
such a pronounced effect in the urothelium, or that the effect is indirect.  
 
Although ACh is released from the urothelium, it is not thought to be stored in 
vesicles. There is also release of neuronal vesicular ACh from cholinergic 
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nerves that have been detected in close proximity to the urothelial cells (Hanna-
Mitchell et al., 2007). Cholinergic agonists applied to cultured urothelial cells can 
elicit an increase in intracellular calcium concentration and evoke the release of 
NO and ATP (Beckel et al., 2006; Kullmann et al., 2008a). Currently the known 
mechanism of action of BoNT/A, is its activity to disable the vesicle docking 
system of exocytosis. In the urothelium, BoNT/A may not directly influence ACh 
release, but may indirectly influence the downstream effect of ACh by inhibiting 
the vesicular release of ATP (Figure 56). The observed change in muscarinic 
receptors following BoNT/A in our study may result partly from a decrease in 
ATP release as well as suburothelial ACh release.  
 
Figure 56: Autocrine / paracrine action of ACh to release ATP from urothelial cells. 
BoNT/A is able to block ATP release and may indirectly alter afferent signalling. 
ACH
M1
M2
M3
+
-
Non-neuronal urothelial 
release of Ach causing 
autocrine release of 
vesicular ATP.
Vesicular ATP release can 
be blocked by BoNT/A.
nAch
nAch
Acetylcholine receptors
ATP
BoNT/A
 
 
 
169 
ATP can also act in an autocrine manner to facilitate its own release from 
urothelial cells (Wang et al., 2005). Once released, ATP can alter the threshold 
for activation of ion channels such as TRPV1 (Birder, 2009). Future functional 
studies looking at changes in ATP concentration and its effect on ACh release 
will be needed to establish if there is crosstalk between different transmitter 
systems.  
 
In bladder efferent nerves, it has been shown that different subtypes of 
muscarinic receptors mediate inhibitory (M2 –M4) and facilitatory effects (M1) on 
ACh release (Somogyi et al., 1994; Andersson and Yoshida, 2003), however 
this has not been shown in the urothelium. Future experiments looking at 
different subtypes of muscarinic receptors and their effect on ACh release in the 
urothelium would help elucidate their functional roles in non–neuronal 
cholinergic transmission.  
 
Despite being the predominant subtype of muscarinic receptor, the functional 
role of M2 receptor in the detrusor muscle and urothelium is unclear (Abrams et 
al., 2006). We found consistent immunostaining of M2 receptors in the 
suburothelium and in muscle layers, similar to that shown by other groups 
(Mukerji et al., 2006; Bschleipfer et al., 2007; Jositsch et al., 2008). 
Suburothelial IR was seen in fibre like structures and on cells with bipolar 
processes, which has also been seen in previous studies.  Other authors have 
shown the presence of M2 receptor mRNA in the urothelium and suburothelium, 
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via Reverse Transcription Polymerase Chain Reaction (RT-PCR) (Bschleipfer et 
al., 2007; Mansfield et al., 2007). Although limited urothelial M2 IR was seen, we 
were not able to evaluate this separately from the suburothelial immunostaining. 
 
Physiological studies have suggested that M2 receptors take on a functional role 
in disease states such as surgically denervated rat bladder (Braverman et al., 
1998) and NDO (Pontari et al., 2004), but this has been disputed by others who 
looked specifically for this in IDO and NDO, finding no change in the receptor 
subtype mediating contraction (Stevens et al., 2007). RT-PCR experiments by 
Mansfield et al. also showed no difference in M2 mRNA expression between 
controls and women with IDO, both in the mucosa (urothelium and 
suburothelium) and in the detrusor (Mansfield et al., 2007). Our results are in 
keeping with these studies, showing no statistical change in M2 IR between 
control subjects and patients with IDO or NDO. The lesser effect of PKC 
phosphorylation on downregulation of M2 
 
receptors may also may also contribute to 
our findings. 
 
One other group has looked at samples of bladder smooth muscle between 
OAB patients and patients undergoing cystectomy for cancer, and found no 
difference in M2 mRNA expression at the dome, but higher expression in the 
non-OAB group at the trigone (Hinata et al., 2004). That study used bladder 
cancer patients as controls. Cancer of the bladder is most frequent in the trigone 
with patients requiring endoscopic surgery for staging prior to radical surgery, 
both of which may have affected receptor expression.  
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The study by Mukerji et al. looked at M2 myofibroblast-like IR in the 
suburothelium and found increases in biopsies from patients with IDO or Painful 
Bladder Syndrome compared to controls, but no change in the urothelium 
(Mukerji et al., 2006). These studies differ in methodology; different antibodies 
were used, capturing potentially different M2 epitopes. Further to this, Mukerji et 
al. quantified MF-like staining, whereas in our study we quantified all 
suburothelial IR.  
 
Following successful administration of BoNT/A in patients with DO, we showed 
an increase in suburothelial M2 IR. As with M1 receptor change, there was 
normalisation of the receptor density values at both 4 and 16 weeks post-
BoNT/A. Separate analysis of the two subgroups showed the main change was 
in the NDO subgroup, whilst the IDO subgroup did not show significant change, 
due to the small IDO subgroup sample size. 
 
It is difficult to explain the pharmaco-physiology behind the increase in M2 
receptor IR following BoNT/A, but a direct effect is unlikely since its mechanism 
of action is to inhibit vesicular release. An indirect consequence to the change of 
various afferent pathways should also be considered. From our results, it is 
apparent that there is considerable plasticity of receptor expression in the 
superficial layers of the bladder, with changes occurring in a relatively short 
period of time. Imaging of efferent pathways in the neuro-muscular junction in 
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the mouse, following application of BoNT/A, has shown that affected motor 
nerve endings undergo extensive nerve sprouting with end plate remodelling (de 
Paiva et al., 1999). 
 
Following prolonged muscarinic receptor stimulation, G protein-coupled 
Receptor Kinase (GRK) phosphorylate agonist occupied receptors, leading to 
binding of arrestins which sterically suppress G protein interaction. Human M2 
receptors have been shown to undergo rapid agonist-dependent 
phosphorylation (Haga et al., 1994; Pals-Rylaarsdam et al., 1995). We 
speculate that BoNT/A reduces ACh release and relieves this agonist-
dependent phosphorylation and internalisation, resulting in greater numbers of 
M1 and M2 receptors. Similarly, muscarinic antagonists have been shown to be 
able to upregulate muscarinic receptor expression (Milligan and Bond, 1997; 
Dowling et al., 2006). Future experiments looking at ACh release following 
stretch or other stimuli, before and after BoNT/A, would help understand the 
normal physiology of the urothelium. 
 
The M3 receptor IR showed significant immunostaining of both urothelium and 
suburothelial structures (neurones and cell bodies), similar to previous studies 
using different antibodies (Mukerji et al., 2006). Some biopsies had sections of 
muscle present which also showed cellular M3 IR. Areas of strong cellular 
staining in the suburothelium were noted close to nerve fibres.  
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We noted a reduction in M3 IR in subjects with DO, which was also significant 
when they were analysed separately as IDO and NDO groups. This is contrary 
to the findings of a previous IHC study, which showed an increased IR in DO 
patients (Mukerji et al., 2006). Reduced M3 mRNA expression in accord with our 
results has been previously demonstrated by PCR in the urothelium and 
suburothelium of patients with IDO, as compared to controls (Mansfield et al., 
2007).  
 
Much of the previous literature has concentrated on the detrusor muscle being 
the site of action of antimuscarinic drugs and potentially the site of 
pathophysiology in OAB and DO. However, the clinical observation that patients 
benefitted during the filling phase, with a reduction of their symptoms of 
urgency, frequency and nocturia could not be explained by an effect on 
efferents alone (Andersson and Yoshida, 2003). Furthermore, the majority of 
patients taking antimuscarinics are able to void to completion. All these facts 
called into question whether the main site of action was just the detrusor muscle 
(Andersson, 2004). 
 
An afferent hypothesis is supported by the inverse associations found between 
muscarinic receptor IR levels, and patients‟ degree of urgency and frequency in 
our study. This suggests that changes in urothelial and suburothelial muscarinic 
receptor expression in patients with DO have clinical relevance. Previous 
correlation with clinical outcomes have been shown with M2 receptors but this 
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was contrary to inverse relationship that we have described (Mukerji et al., 
2006).  
 
Recent radioligand binding studies looking at antimuscarinic binding in 
urothelium, suburothelium and detrusor have demonstrated that antimuscarinics 
exhibit equal affinity for both urothelium/suburothelium and detrusor (Mansfield 
et al., 2008). Our results show that muscarinic receptors are present in the 
urothelium and suburothelium with decreases occurring in patients with DO, with 
normalisation of M1 and M2 and increased urothelial M1 and M3 receptors after 
BoNT/A. The therapeutic efficacy of antimuscarinic drugs may similarly be 
based on their ability to antagonise urothelial and suburothelial muscarinic 
receptors, preventing overstimulation by ACh. The greater efficacy of BoNT/A 
may be due to its effect on multiple pathways as well as its inhibition of ACh 
release, whereas anticholinergics reduce ACh binding to its receptor.  
 
Our finding of changes in the superficial layer fits with the emerging hypothesis 
that the urothelium acts as a mechanosensor, releasing ATP and ACh that 
activates purinergic and muscarinic receptors in suburothelial nerves This in 
turn conveys information on bladder fullness to the central nervous system 
(Andersson and Arner, 2004; Apostolidis et al., 2006; Chancellor et al., 2008). In 
conditions of increased sensory nerve transmission such as OAB, IDO and 
NDO, there is increased release of ATP and ACh from the urothelium and 
suburothelium, which activate P2X3 and muscarinic receptors to increase 
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afferent nerve activity. This would account for the higher frequency of bladder 
contractions reported in human and animal models of spinal cord injury (Smith 
et al., 2003; Khera et al., 2004; Smith et al., 2008). We speculate that BoNT/A 
reduces the release of ATP and ACh and therefore helps to normalise P2X3, 
suburothelial M1, M2 and urothelial M1 and M3 populations.  
 
Researchers who studied bladder contraction with carbachol found that greater 
contractions are seen when the urothelium is removed. They have proposed 
that a UDIF modulates the contractility of the detrusor muscle (Hawthorn et al., 
2000; Templeman et al., 2002; Chaiyaprasithi et al., 2003). It is known that 
muscarinic agonists mediate the release of this factor. A reduction of muscarinic 
receptors in the urothelium as seen in DO patients may inhibit the release of 
UDIF predisposing towards uninhibited reflex detrusor contractions.  
 
Activation of superficial muscarinic receptors in the rat bladder wall by an 
agonist (Oxotermorine methiodide) showed it could both inhibit as well as excite 
frequency of voiding, depending on its concentration (Kullmann et al., 2008a). 
Low concentrations of the agonist inhibited voiding frequency, whereas high 
concentrations elicited excitatory effects. Capsaicin pre-treatment prevented any 
effect by the agonist. The inhibitory effect seemed to be mediated by NO (effect 
diminished by L-NAME), whereas the excitatory effects were mediated partly by 
ATP. This study indicates that an increase / decrease in muscarinic receptors 
could give rise to increased afferent activity.  
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Daly et.al showed stimulation of mouse bladder muscarinic receptors with 
bethanechol, carbachol and indirectly with physostigmine significantly inhibited 
the afferent response to bladder distention (Daly et al., 2010). These effects 
were reversed with atropine but not by 4-diphenlacetoxy-N-methylpiperidine (4-
DAMP), a M3 receptor antagonist, suggesting other muscarinic receptors are 
responsible for the inhibition of afferent responses. This is in line with our 
findings of an increase of M1 and M2 receptors after BoNT/A, with a reduction in 
clinical urgency symptoms and an increase in mean cystometric capacity.  
 
Further investigation of the underlying muscarinic modulatory mechanisms, 
specifically whether a particular mAChR subtype (M1–M5) or a mAChR subtype 
located at a particular site (urothelium or nerves) is involved, might help to 
identify new targets for the treatment of overactive bladder (Kullmann et al., 
2008a). Afferent M1 and M2 receptors may facilitate the therapeutic response 
seen in response to antimuscarinics and BoNT/A. 
 
The administration of BoNT/A did not change the suburothelial M3 IR at any time 
point, but did show an increase in the urothelial M3 IR at 16 weeks. These 
results are in contrast to decreases in suburothelial P2X3 and TRPV1 IR after 
BoNT/A, but did not show in the urothelium. We know from this previous study 
that BoNT/A does not cause a significant change in the suburothelial neuronal 
population, as measured by the IR of the pan-neuronal marker PGP 9.5 
 
177 
(Apostolidis et al., 2005b) and a further study showed no evidence of 
apoptosis(Kessler et al., 2009).  
 
The increase in urothelial M3 IR cannot be explained by a direct action of 
BoNT/A, as SNAP-25 has not been shown to be found in the urothelium in our 
study or in previous studies (Chancellor et al., 2008). This observation may 
come about by a compensatory paracrine mechanism in a low-frequency 
functioning bladder with reduced release of neuronal ACh in the suburothelium. 
BoNT/A reduction of some sensory receptor levels (P2X3 and TRPV1) and 
increase in muscarinic receptor levels (M1, M2 and urothelial M3) points to a 
complex cascade mechanism of action, with several indirect changes resulting 
from the suburothelial and detrusor vesicular neurotransmitter blockade. Future 
work is needed to help us understand how these occur.  
 
Other potential targets of BoNT/A include arachidonic acid, a potent fusogen, 
which facilitates vesicular fusion and exocytosis (Karli et al., 1990), enabling 
ACh release (Nishio et al., 1996). BoNT/A has been shown to block arachidonic 
acid release from membrane stores (Ray et al., 1993), which may partly prevent 
ACh release from the urothelium.  
 
From the multiple changes noted in muscarinic receptors, the most plausible 
explanation for the clinical efficacy of BTX-A in the treatment of human detrusor 
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overactivity is that it impairs the release of ATP and ACh in the superficial layers 
of the bladder.   
 
SNAP-25 
When injected, the diffusion of BoNT/A is visually apparent in the superficial 
layer by the addition of indigo carmine (Schulte-Baukloh and Knispel, 2005). In 
our study, SNAP-25 IR was seen in the suburothelium and muscle layers as an 
extensive network of SNAP-25 fibres. However SNAP-25 fibres were not seen 
within the urothelium, implicating the suburothelium being the main site of action 
within the afferent layers of the bladder. BoNT/A uses secretory vesicle protein 
2 (SV2) as its protein receptor on the neurone surface (Dong et al., 2006) to 
become internalised. Without SNAP-25 being present, BoNT/A could not act 
and consequently SNAP-25 is a good marker to delineate the site of action of 
BoNT/A.  
 
Comparison of SNAP-25 IR in suburothelium and detrusor in our study showed 
that there was 43% more IR density within the suburothelial layer. This suggests 
that suburothelial layer may play a critical role in the mechanism of action of 
BoNT/A. Studies have shown that BoNT/A inhibits release of ATP from the 
urothelial side of the bladder, implying that part of its action is in the 
urothelial/suburothelial layer (Khera et al., 2004) and supporting our hypothesis 
that at BoNT/A has an effect on urothelium and suburothelium. A limitation of 
our study is that we could only examine the inner superficial detrusor layer due 
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to the limited size of the flexible cystoscope biopsies, therefore we do not know 
if this finding applies to the larger outer part of the detrusor muscle. 
 
Following BoNT/A administration, there was no change in SNAP-25 IR at 4 or 
16 weeks. The antibody we used was not able to differentiate between SNAP-
25 and the cleaved product SNAP-25A. This limitation has been noted by other 
authors, and they were able to demonstrate the cleavage products by 
immunoprecipitation studies in one patient 11 months after injection (Schulte-
Baukloh et al., 2007). They found detection of SNAP-25A challenging due to its 
minute concentration and the prolonged interval (between 1-30 months) 
following injection and follow-up biospsies being taken, resulting in it being 
detectable in only 4 out of 7 patients analysed. Repeating this work in the 
suburothelium was not possible, as commercial antibodies are currently 
unavailable for SNAP-25A.  
 
BoNT/A acts on ubiquitous intracellular targets required for any SNARE 
dependent neurotransmitter release (Ashton and Dolly, 1988). Our current 
understanding of the afferent pathways in the bladder is just beginning. There 
are numerous neurotransmitters systems in the urothelium/suburothelium; those 
that are  potentially affected by BoNT/A that have yet to be identified. 
 
Animal studies have shown BoNT/A reduces distension evoked urothelial 
release of ATP in a rat model of NDO (Khera et al., 2004). Other 
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neurotransmitter systems, including CGRP, have similarly been inhibited by 
BoNT/A (Chuang et al., 2004). Human urinary NGF levels have been found to 
be elevated in IDO and NDO, with these levels falling after successful treatment 
with BoNT/A (Liu et al., 2008). These examples all illustrate the complex 
interactions of BoNT/A on the afferent pathways, as well as its multifactorial 
mechanism of action in DO. 
 
Our study was able to identify the location and density of SNAP-25 in the 
superficial layers of the bladder and suggests that part of BoNT/A clinical 
effectiveness may be due to its action on SNAP-25 in the suburothelium.  
 
Neuropeptide Y 
NPY is a key co-transmitter of ACh in the urinary tract. It has been found to be 
present with nerves positive for VAChT immunostaining (Dixon et al., 2000), 
both in the suburothelium as well as on the detrusor of the human bladder. Our 
results have shown NPY IR present within the apical urothelium and in a 
suburothelial nexus of fibre like structures. Findings similar to ours have been 
seen in previous studies looking at suburothelium (Iwasa, 1993; Dixon et al., 
2000).  
 
This study demonstrated a significant increase in NPY IR in the suburothelium 
in patients with DO compared to asymptomatic controls. Given the close 
association of ACh and NPY, this would be in accordance with previous studies 
 
181 
showing an increased urothelial / suburothelial ACh release with age and stretch 
(Yoshida et al., 2006; Yoshida et al., 2008). Similarly, men with bladder neck 
dyssynergia have been shown to have a greater density of suburothelial NPY 
immunoreactive neurones (Crowe et al., 1995). 
 
Rat bladders have shown depletion of NPY IR following prolonged distension, 
suggesting that NPY is a neurotransmitter involved in signal transduction 
(Lasanen et al., 1992). Postganglionic denervation of the bladder in rats resulted 
in a decrease in NPY nerves both in the suburothelium and detrusor, whereas 
preganglionic lesions with decentralisation resulted in an increase in NPY IR 
fibres in the bladder wall (Mattiasson et al., 1985). Radiation injury (>25Gy) has 
shown significant increases in the density of rat detrusor NPY IR nerves (Crowe 
et al., 1996).  
 
Previous studies looking at human detrusor muscle had found decreases in 
NPY IR nerve fibres in patients with meningomyelocele and spinal cord injury 
associated with partial nerve degeneration, as compared to women with stress 
urinary incontinence (Haferkamp et al., 2006). Our biopsies have not shown any 
evidence of degeneration, with no change in PGP 9.5 (Apostolidis et al., 2005b).  
 
There is variability in the findings of NPY IR nerves and how they change in 
disease states. Although they have been noted in suburothelium, few studies 
have tried to quantify these nerves, especially in humans. This study is the first 
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to describe changes in suburothelial NPY with DO. As almost all nerves that 
contain ACh contain NPY (Dixon et al., 2000), it would be reasonable to 
presume that ACh containing nerves in the suburothelium would also be 
increased in DO.  
 
The role of NPY in the urothelium is speculated to involved detection of stretch, 
however functional studies involving NPY (> 1 nM) have shown efferent effects 
by enhancing the force and frequency of spontaneous contractions and 
generating a rise in the resting tone of the detrusor; at higher concentrations 
NPY initiated detrusor contraction (Iravani and Zar, 1994). Pharmacological 
studies show NPY having two opposing actions, inhibition of adrenergic 
transmission and prevention of cholinergic disinhibition of NA release (Tran et 
al., 1994).  
 
Following successful BoNT/A, our results showed a steady decrease in NPY IR 
towards control levels, although this was not statistically significant (baseline vs. 
16 weeks, student t-test, p=0.07). NPY is found in dense core vesicles in 
suburothelial nerves and are released with neuronal activity however it is not 
known if they are SNARE dependent. It seems possible that BoNT/A decreases 
NPY IR similarly to its effect on ACh and ATP release, through its inhibitory 
action on SNARE vesicle release.   
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Although changes in NPY IR were noted in patients with DO and after BoNT/A, 
it is difficult to speculate about its role in the pathophysiology and treatment of 
DO without understanding normal NPY function. Future studies looking at the 
functional role of NPY or studies of KO mice will give us a greater understanding 
of its physiological function within the bladder. 
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Chapter 16 - Summary and Conclusions  
Our key experimental findings show that: 
i. M1 and M3 muscarinic receptor IR density is decreased in patients with 
IDO and NDO, compared to control subjects.  
ii. Muscarinic receptors M1, M2 and urothelial M3 IR increase following 
BoNT/A.  
iii. No SNAP-25 IR is present within the urothelium. 
iv. SNAP-25 IR is present extensively in the suburothelium, suggesting this 
may be the afferent site of action of BoNT/A.  
v. There is a greater SNAP-25 IR density in the suburothelium compared to 
muscle. 
vi. NPY, a cholinergic co-transmitter, has an increased IR density in DO 
compared to control subjects.  
vii. NPY IR decreases after BoNT/A. 
viii. There is a negative correlation between frequency and urgency and 
suburothelial muscarinic receptor density.  
 
1. Our findings support the hypothesis that the urothelium and 
suburothelium play a crucial role in the afferent innervation of the 
bladder. It is likely that there is significant cross talk between different 
neurotransmitter systems, allowing modulation of the afferent signal to 
the CNS.  We have identified key differences in these structures between 
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control subjects and patients, implying that they have a role in the 
pathophysiology of DO.  
 
2. We had hypothesised that SNAP-25 would be present in the superficial 
layers of the bladder due to BoNT/A clinical efficacy in ameliorating 
urinary sensory symptoms. We were able to show the relative abundance 
of SNAP-25 labelled nerves in the suburothelium and in the muscle 
layers. SNAP-25 IR was not present in the urothelium and as expected 
its IR did not change in BoNT/A treated patients or in the control group.  
 
3. It is clear from our experimental findings that BoNT/A has a significant 
effect on afferent pathways via its interactions with neuropeptides, 
receptors and neurotransmitters. BoNT/A does not just provide motor 
blockade at the smooth muscle layer, as originally proposed.  
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Figure 57: A) Summary of findings in Detrusor Overactivity found in the urothelium and 
suburothelium. B) Following BoNT/A treatment, all of neurotransmitters and receptors 
return towards control levels apart from M3 and connexin 43. Bl = basement layer, mf = 
myofibroblast. 
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Chapter 17 - Limitations 
Our current experimental work was confined to the superficial layers of bladder 
due to the samples available for study. Possible future work looking at the outer 
muscle layer would help understand the effect of BoNT/A on the entire bladder. 
The effect on the efferent layer is likely to be considerable given the wide 
mechanism of action of BoNT/A.  
 
Immunohistochemistry  
We are aware of the methodological restrictions of semi-quantitative 
immunohistochemistry – but defend the position that it is the only available 
method to quantitatively examine the suburothelial space selectively. Slight 
differences in staining intensities are regarded as non-specific, due to the limited 
accuracy of the method. 
 
Quantification of elongated structures is particularly difficult, as their orientation 
in the section determines their representation either as punctate or as fibre-like 
structures. Therefore, we used standardised procedures for tissue processing, 
staining and analysis during the entire study. Myofibroblast density increases 
towards the bladder neck (van der et al., 2004), so biopsies were taken 
consistently from same area. Theoretical limitations of the size of biopsies 
obtained via flexible cystoscopy have been addressed in several previous 
studies using identical protocols (Brady et al., 2004a; Apostolidis et al., 2005b; 
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Apostolidis et al., 2008) but the clinical ease of obtaining these specimens has 
enabled this work which would not otherwise have been possible. 
  
Concerns have recently been raised about the specificity of muscarinic receptor 
antibodies used for immunohistochemistry (Jositsch et al., 2008; Pradidarcheep 
et al., 2009). It has been proposed that if multiple antibodies raised against 
different epitopes of the receptor show a similar pattern of IR, this could be 
considered evidence of their selectivity (Michel et al., 2009), supporting partly 
the specificity of at least our suburothelial immunostaining. Moreover, the use of 
negative controls and the apparently specific cellular immunostaining of mouse 
cerebellar and heart tissue (positive controls), together with a similar trend of 
muscarinic receptor mRNA changes seen in our biopsies (results not included 
here) and other studies, add to the argument for specificity of our results. 
  
Antimuscarinic medication  
At least half our patient population were on antimuscarinic medication when the 
study began; this percentage dropped to about one third of the patients at the 4- 
and 16-week follow-up time points. Although a synergistic effect of the 
concomitant use of antimuscarinic medication with BoNT/A was a theoretical 
possibility, our study showed both the expression of receptors and the clinical 
parameters examined before and after treatment were found to be no different 
between patients who use and those who did not use antimuscarinics. This may 
be in accordance with in-vitro animal experiments showing that the blockade of 
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urothelial and suburothelial muscarinic receptors had no effect on afferent 
discharge or response to bladder distension (Daly et al., 2010). Larger, 
specifically designed studies are needed to examine whether antimuscarinics 
have a synergistic effect with BoNT/A. 
 
We understand that a further confirmatory technique would be useful, and we 
are currently looking at other experimental techniques like RT-PCT to detect any 
changes in muscarinic mRNA expression before and after BoNT/A.  
 
Future Work 
The use of PCR or western blot gel electrophoresis would provide confirmation 
of the findings of our study and would be the next logical step. We were limited 
by the biopsy sizes that could be taken from patients who were involved in our 
study. Double staining experiments would help elucidate whether muscarinic 
receptors are present on interstitial cells / myofibroblasts and would be a good 
future study to determine if these cells are involved in the afferent transduction 
process.  
 
The site and role of the other muscarinic receptors M4 and M5 in the urothelium / 
suburothelium are yet to be elucidated.  
 
As we learn more about the superficial layers of the bladder, we will develop a 
greater understanding about the individual systems and the sensory modalities 
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they convey, and be able to compare these with structures like the dermis which 
have been studied more extensively. Studying conditions like OAB and DO with 
therapeutic drugs like BoNT/A allow us to gain insight into the normal physiology 
of the bladder. The afferent neurotransmitter pathways of the bladder are yet to 
have their functional roles fully elucidated. The transduction pathways 
responsible for sensing heat, cold, stretch or pain are still unknown. Whether 
upregulation in one sensory pathway in the bladder can affect others is a key 
question in the patho-physiology of disease state. There are many questions yet 
to be answered. 
 
Although understanding the physiology is important, manipulating it to help our 
patients improve their symptoms and quality of life is the ultimate goal for 
clinicians. Drug treatments for OAB and DO run into many billions of pounds 
and until BoNT/A (currently unlicensed), there had been little progress in new 
classes of medication. Currently our therapies are limited to antimuscarinic 
medications or major surgery, where efficacy is often limited and side-effects 
considerable. Targeting of urothelial/suburothelial receptors and ACh release 
mechanisms will permit testing of new drugs and allow us to develop novel 
strategies, eventually allowing development of targeted treatments efficacious 
solely on the sensory afferents.  
 
The bladder gives an impression of simplicity, but just under the surface is a 
remarkably intricate sensory organ.  
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